

Amyloid deposition precedes tangle formation in a triple disease

Neurobiology of Aging

24, 1063-1070

DOI: [10.1016/j.neurobiolaging.2003.08.012](https://doi.org/10.1016/j.neurobiolaging.2003.08.012)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Future directions in the treatment of Alzheimer's disease. Expert Opinion on Investigational Drugs, 2004, 13, 303-314.	4.1	32
2	Intracerebroventricular passive immunization in transgenic mouse models of Alzheimer's disease. Expert Review of Vaccines, 2004, 3, 717-725.	4.4	15
3	Chasing genes in Alzheimer's and Parkinson's disease. Human Genetics, 2004, 114, 413-438.	3.8	46
4	A β 2 Immunotherapy Leads to Clearance of Early, but Not Late, Hyperphosphorylated Tau Aggregates via the Proteasome. Neuron, 2004, 43, 321-332.	8.1	746
5	Dementia with Lewy Bodies: Molecular Pathogenesis and Implications for Classification. Journal of Geriatric Psychiatry and Neurology, 2004, 17, 112-119.	2.3	39
6	The Role of Caspase Cleavage of Tau in Alzheimer Disease Neuropathology. Journal of Neuropathology and Experimental Neurology, 2005, 64, 104-112.	1.7	172
7	Correlation between astrocyte apoptosis and Alzheimer changes in gray matter lesions in Alzheimer's disease. Journal of Alzheimer's Disease, 2005, 6, 623-632.	2.6	50
8	Immunotherapy for Alzheimer's disease and other dementias. Current Opinion in Neurology, 2005, 18, 720-725.	3.6	17
9	Alzheimer's Disease: Current and Future Treatments. , 2005, , 329-354.		1
10	Correlation between tau phosphorylation sites and tangle morphology in Alzheimer's disease. Psychogeriatrics, 2005, 5, 22-35.	1.2	2
11	Stimulation of PGE2 receptors EP2 and EP4 protects cultured neurons against oxidative stress and cell death following A β -amyloid exposure. European Journal of Neuroscience, 2005, 22, 2199-2206.	2.6	116
12	Relationship of neurofibrillary pathology to cerebral amyloid angiopathy in Alzheimer's disease. Neuropathology and Applied Neurobiology, 2005, 31, 414-421.	3.2	41
13	Quantification of the A β 2 peptide in Alzheimer's plaques by laser dissection microscopy combined with mass spectrometry. Journal of Mass Spectrometry, 2005, 40, 193-201.	1.6	43
14	The Role of Apoptotic Pathways in Alzheimer's Disease Neurodegeneration and Cell Death. Current Alzheimer Research, 2005, 2, 389-402.	1.4	106
15	The Dualistic Nature of Immune Modulation In Alzheimer's Disease: Lessons from the Transgenic Models. Current Pharmaceutical Design, 2005, 11, 3335-3352.	1.9	3
16	Fasciclin II Signals New Synapse Formation through Amyloid Precursor Protein and the Scaffolding Protein dX11/Mint. Journal of Neuroscience, 2005, 25, 5943-5955.	3.6	155
17	Chronic nicotine administration exacerbates tau pathology in a transgenic model of Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 3046-3051.	7.1	188
18	The Contribution of Microscopy to the Study of Alzheimer's Disease, Amyloid Plaques and A β 2 Fibrillogenesis. , 2005, 38, 1-44.		4

#	ARTICLE	IF	CITATIONS
19	Alzheimer's disease: A β , tau and synaptic dysfunction. Trends in Molecular Medicine, 2005, 11, 170-176.	6.7	388
20	Tau phosphorylation: physiological and pathological consequences. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2005, 1739, 280-297.	3.8	379
21	Preserved synaptic vesicle recycling in hippocampal neurons in a mouse Alzheimer's disease model. Biochemical and Biophysical Research Communications, 2005, 330, 34-38.	2.1	13
22	Age- and region-dependent alterations in A β -degrading enzymes: implications for A β -induced disorders. Neurobiology of Aging, 2005, 26, 645-654.	3.1	284
23	Endogenous A β -amyloid peptide synthesis modulates cAMP response element-regulated gene expression in PC12 cells. Neuroscience, 2005, 135, 1193-1202.	2.3	24
24	Early correlation of microglial activation with enhanced tumor necrosis factor-alpha and monocyte chemoattractant protein-1 expression specifically within the entorhinal cortex of triple transgenic Alzheimer's disease mice. Journal of Neuroinflammation, 2005, 2, 23.	7.2	213
25	Transgenic models of Alzheimer's disease: Learning from animals. NeuroRx, 2005, 2, 423-437.	6.0	180
26	Aberrant accentuation of neurofibrillary degeneration in the hippocampus of Alzheimer's disease with amyloid precursor protein 717 and presenilin-1 gene mutations. Journal of the Neurological Sciences, 2005, 234, 55-65.	0.6	11
27	Pathophysiology of Alzheimer's Disease. Neuroimaging Clinics of North America, 2005, 15, 727-753.	1.0	68
29	A Dynamic Relationship between Intracellular and Extracellular Pools of A β . American Journal of Pathology, 2006, 168, 184-194.	3.8	232
30	High cholesterol content in neurons increases BACE, A β -amyloid, and phosphorylated tau levels in rabbit hippocampus. Experimental Neurology, 2006, 200, 460-467.	4.1	144
31	The cAMP-specific phosphodiesterase 4B mediates A β -induced microglial activation. Neurobiology of Aging, 2006, 27, 691-701.	3.1	37
32	Search for Solutions: Animal Models of Disease. The Consultant Pharmacist, 2006, 21, 364-378.	0.4	1
33	Models of Alzheimer's Disease. , 2006, , 121-134.		2
34	Genetically Engineered Mouse Models of Neurodegenerative Disorders. , 2006, , 371-408.		0
35	Animal Models of Alzheimer's Disease. , 2006, , 1-73.		0
36	Immunotherapy for Alzheimer's Disease and Other Dementias. Clinical Neuropharmacology, 2006, 29, 22-27.	0.7	7
37	Drug discovery in dementia: the role of rodent models. Nature Reviews Drug Discovery, 2006, 5, 956-970.	46.4	189

#	ARTICLE	IF	CITATIONS
38	β 2-Protein/A4 deposits are not associated with hyperphosphorylated tau in somatostatin neurons in the hypothalamus of Alzheimer's disease patients. <i>Acta Neuropathologica</i> , 2006, 111, 126-138.	7.7	17
39	A decade of modeling Alzheimer's disease in transgenic mice. <i>Trends in Genetics</i> , 2006, 22, 281-289.	6.7	266
40	The Role of Tau Phosphorylation in the Pathogenesis of Alzheimer's Disease. <i>Current Alzheimer Research</i> , 2006, 3, 449-463.	1.4	124
41	Tau Therapeutic Strategies for the Treatment of Alzheimer's Disease. <i>Current Topics in Medicinal Chemistry</i> , 2006, 6, 579-595.	2.1	122
42	Challenges in Neuronal Apoptosis. <i>Current Alzheimer Research</i> , 2006, 3, 377-391.	1.4	74
43	Genetically Modified Mice Models for Alzheimer's Disease. <i>Current Topics in Medicinal Chemistry</i> , 2006, 6, 609-627.	2.1	14
44	Pathways by Which A β Facilitates Tau Pathology. <i>Current Alzheimer Research</i> , 2006, 3, 437-448.	1.4	170
45	Mapping genetic modulators of amyloid plaque deposition in TgCRND8 transgenic mice. <i>Human Molecular Genetics</i> , 2006, 15, 2313-2323.	2.9	25
47	Nonviral A β DNA vaccine therapy against Alzheimer's disease: Long-term effects and safety. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 9619-9624.	7.1	66
48	Enhanced Ryanodine Receptor Recruitment Contributes to Ca ²⁺ Disruptions in Young, Adult, and Aged Alzheimer's Disease Mice. <i>Journal of Neuroscience</i> , 2006, 26, 5180-5189.	3.6	305
49	Selectively increased oxidative modifications mapped to detergent-insoluble forms of A β and β -tubulin in Alzheimer's disease. <i>FASEB Journal</i> , 2006, 20, 1473-1483.	0.5	29
50	Calcium-mediated Transient Phosphorylation of Tau and Amyloid Precursor Protein Followed by Intraneuronal Amyloid- β Accumulation. <i>Journal of Biological Chemistry</i> , 2006, 281, 39907-39914.	3.4	99
51	Advances on the Understanding of the Origins of Synaptic Pathology in AD. <i>Current Genomics</i> , 2007, 8, 486-508.	1.6	32
52	Recent Advances in the Development of Amyloid Imaging Agents. <i>Current Topics in Medicinal Chemistry</i> , 2007, 7, 1773-1789.	2.1	79
53	Learning Decreases A β *56 and Tau Pathology and Ameliorates Behavioral Decline in 3xTg-AD Mice. <i>Journal of Neuroscience</i> , 2007, 27, 751-761.	3.6	123
54	The Novel β 3 Secretase Inhibitor N-[cis-4-[(4-Chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide (MRK-560) Reduces Amyloid Plaque Deposition without Evidence of Notch-Related Pathology in the Tg2576 Mouse. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007, 320, 552-558.	2.5	84
55	Anti-A β 11 Antibody Binds to Different β -Amyloid Species, Inhibits Fibril Formation, and Disaggregates Preformed Fibrils but Not the Most Toxic Oligomers. <i>Journal of Biological Chemistry</i> , 2007, 282, 22376-22386.	3.4	90
56	Progesterone and Estrogen Regulate Alzheimer-Like Neuropathology in Female 3xTg-AD Mice. <i>Journal of Neuroscience</i> , 2007, 27, 13357-13365.	3.6	295

#	ARTICLE	IF	CITATIONS
58	Increase in $\text{A}\beta$ -Amyloid Levels in Cerebrospinal Fluid of Children with Down Syndrome. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007, 24, 369-374.	1.5	33
60	Imaging the $\text{A}\beta$ -Related Neurotoxicity of Alzheimer Disease. <i>Archives of Neurology</i> , 2007, 64, 1467.	4.5	80
61	Impact of amyloid imaging on drug development in Alzheimer's disease. <i>Nuclear Medicine and Biology</i> , 2007, 34, 809-822.	0.6	115
62	Alzheimer disease: Amyloidogenesis, the presenilins and animal models. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2007, 1772, 285-297.	3.8	119
63	Prophylactic treatment with paroxetine ameliorates behavioral deficits and retards the development of amyloid and tau pathologies in 3xTgAD mice. <i>Experimental Neurology</i> , 2007, 205, 166-176.	4.1	159
64	Regeneration in a Degenerating Brain: Potential of Allopregnanolone as a Neuroregenerative Agent. <i>Current Alzheimer Research</i> , 2007, 4, 510-517.	1.4	51
65	Lithium Reduces Tau Phosphorylation but Not $\text{A}\beta$ or Working Memory Deficits in a Transgenic Model with Both Plaques and Tangles. <i>American Journal of Pathology</i> , 2007, 170, 1669-1675.	3.8	191
66	Small molecule inhibitors of $\text{A}\beta$ assembly. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2007, 14, 185-197.	3.0	59
67	Effect of HMG-CoA Reductase Inhibitors on $\text{A}\beta$ -Amyloid Peptide Levels. <i>CNS Drugs</i> , 2007, 21, 449-462.	5.9	53
69	Morbo di Alzheimer. <i>EMC - Neurologia</i> , 2007, 7, 1-26.	0.0	0
70	Drug Effects on Learning and Memory. , 2007, , 877-942.		1
71	Mitochondrial Oxidative Stress Causes Hyperphosphorylation of Tau. <i>PLoS ONE</i> , 2007, 2, e536.	2.5	291
72	Does Aluminum Contribute to Alzheimer Disease Directly, Indirectly, or At All?. <i>Journal of Alzheimer's Disease</i> , 2007, 11, 431-432.	2.6	3
73	Neuronal LR11/sorLA expression is reduced in mild cognitive impairment. <i>Annals of Neurology</i> , 2007, 62, 640-647.	5.3	94
74	Modeling behavioral and neuronal symptoms of Alzheimer's disease in mice: A role for intraneuronal amyloid. <i>Neuroscience and Biobehavioral Reviews</i> , 2007, 31, 125-147.	6.1	202
75	Novel rat Alzheimer's disease models based on AAV-mediated gene transfer to selectively increase hippocampal $\text{A}\beta$ levels. <i>Molecular Neurodegeneration</i> , 2007, 2, 11.	10.8	61
76	Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. <i>Nature Reviews Neuroscience</i> , 2007, 8, 663-672.	10.2	1,866
78	Genetically augmenting tau levels does not modulate the onset or progression of $\text{A}\beta$ pathology in transgenic mice. <i>Journal of Neurochemistry</i> , 2007, 102, 1053-1063.	3.9	70

#	ARTICLE	IF	CITATIONS
79	Collapsin response mediator protein-2 hyperphosphorylation is an early event in Alzheimer's disease progression. <i>Journal of Neurochemistry</i> , 2007, 103, 1132-1144.	3.9	158
80	Alzheimer neurofibrillary degeneration: significance, etiopathogenesis, therapeutics and prevention. <i>Journal of Cellular and Molecular Medicine</i> , 2008, 12, 38-55.	3.6	200
81	Intermittent fasting and caloric restriction ameliorate age-related behavioral deficits in the triple-transgenic mouse model of Alzheimer's disease. <i>Neurobiology of Disease</i> , 2007, 26, 212-220.	4.4	474
82	Anatomical and Functional Phenotyping of Mice Models of Alzheimer's Disease by MR Microscopy. <i>Annals of the New York Academy of Sciences</i> , 2007, 1097, 12-29.	3.8	32
83	Transgenic animal models of neurodegenerative diseases and their application to treatment development. <i>Advanced Drug Delivery Reviews</i> , 2007, 59, 1093-1102.	13.7	77
84	Soluble protein oligomers as emerging toxins in Alzheimer's and other amyloid diseases. <i>IUBMB Life</i> , 2007, 59, 332-345.	3.4	289
85	Role of Cyclin-Dependent Kinase 5 in the Neurodegenerative Process Triggered by Amyloid-Beta and Prion Peptides: Implications for Alzheimer's Disease and Prion-Related Encephalopathies. <i>Cellular and Molecular Neurobiology</i> , 2007, 27, 943-957.	3.3	66
86	Plaques, Tangles, and Memory Loss in Mouse Models of Neurodegeneration. <i>Behavior Genetics</i> , 2007, 37, 79-100.	2.1	130
87	Tauopathy models and human neuropathology: similarities and differences. <i>Acta Neuropathologica</i> , 2007, 115, 39-53.	7.7	44
88	Stable Expression of a Novel Fusion Peptide of Thioredoxin-1 and Aβ-Inhibiting Peptide Protects PC12 Cells from Intracellular Amyloid-Beta. <i>Journal of Molecular Neuroscience</i> , 2007, 33, 180-188.	2.3	9
89	The Wnt Antagonist, Dickkopf-1, as a Target for the Treatment of Neurodegenerative Disorders. <i>Neurochemical Research</i> , 2008, 33, 2401-2406.	3.3	55
90	Decreased drebrin mRNA expression in Alzheimer disease: Correlation with tau pathology. <i>Journal of Neuroscience Research</i> , 2008, 86, 2292-2302.	2.9	44
91	Review on the APP/PS1KI mouse model: intraneuronal Aβ ² accumulation triggers axonopathy, neuron loss and working memory impairment. <i>Genes, Brain and Behavior</i> , 2008, 7, 6-11.	2.2	47
92	Conditionally inducible tau mice – designing a better mouse model of neurodegenerative diseases. <i>Genes, Brain and Behavior</i> , 2008, 7, 12-27.	2.2	14
94	Increased intraneuronal resting [Ca ²⁺] in adult Alzheimer's disease mice. <i>Journal of Neurochemistry</i> , 2008, 105, 262-271.	3.9	142
95	Estrogen anti-inflammatory activity in brain: A therapeutic opportunity for menopause and neurodegenerative diseases. <i>Frontiers in Neuroendocrinology</i> , 2008, 29, 507-519.	5.2	261
96	Detailed immunohistochemical characterization of temporal and spatial progression of Alzheimer's disease-related pathologies in male triple-transgenic mice. <i>BMC Neuroscience</i> , 2008, 9, 81.	1.9	199
97	Brain oxidative stress in a triple-transgenic mouse model of Alzheimer disease. <i>Free Radical Biology and Medicine</i> , 2008, 44, 2051-2057.	2.9	304

#	ARTICLE	IF	CITATIONS
98	Free radical-mediated damage to brain in Alzheimer's disease and its transgenic mouse models. Free Radical Biology and Medicine, 2008, 45, 219-230.	2.9	95
99	Ibuprofen reduces A β ² , hyperphosphorylated tau and memory deficits in Alzheimer mice. Brain Research, 2008, 1207, 225-236.	2.2	191
100	Non-tau based neuronal degeneration in Alzheimer's disease – an immunocytochemical and quantitative study in the supragranular layers of the middle temporal neocortex. Brain Research, 2008, 1213, 152-165.	2.2	39
101	Regenerative potential of allopregnanolone. Brain Research Reviews, 2008, 57, 398-409.	9.0	95
102	The ubiquitin–proteasome system in Alzheimer's disease. Journal of Cellular and Molecular Medicine, 2008, 12, 363-373.	3.6	214
103	Motor alterations are reduced in mice lacking the PARK2 gene in the presence of a human FTDP-17 mutant form of four-repeat tau. Journal of the Neurological Sciences, 2008, 275, 139-144.	0.6	7
104	Gender-Specific Neuroimmunoendocrine Aging in a Triple-Transgenic 3 \times Tg-AD Mouse Model for Alzheimer's Disease and Its Relation with Longevity. NeuroImmunoModulation, 2008, 15, 331-343.	1.8	79
105	Development, Optimization and Use of Preclinical Behavioral Models to Maximize the Productivity of Drug Discovery for Alzheimer's Disease. , 2008, , 93-157.		10
106	A genetic interaction between the APP and Dab1 genes influences brain development. Molecular and Cellular Neurosciences, 2008, 37, 178-186.	2.2	35
107	A β ² inhibits the proteasome and enhances amyloid and tau accumulation. Neurobiology of Aging, 2008, 29, 1607-1618.	3.1	316
108	Memory and exploratory impairment in mice that lack the Park-2 gene and that over-express the human FTDP-17 mutant Tau. Behavioural Brain Research, 2008, 189, 350-356.	2.2	12
109	Chronic Neuron-Specific Tumor Necrosis Factor-Alpha Expression Enhances the Local Inflammatory Environment Ultimately Leading to Neuronal Death in 3 \times Tg-AD Mice. American Journal of Pathology, 2008, 173, 1768-1782.	3.8	205
110	Blocking A β ² Accumulation Delays the Onset and Progression of Tau Pathology via the C Terminus of Heat Shock Protein70-Interacting Protein: A Mechanistic Link between A β ² and Tau Pathology. Journal of Neuroscience, 2008, 28, 12163-12175.	3.6	123
111	Therapeutic Approaches for the Treatment of Alzheimer's Disease: An Overview. , 2007, , 1-24.		5
112	Increased A β ⁴² Production Sensitizes Neuroblastoma Cells for ER Stress Toxicity. Current Alzheimer Research, 2008, 5, 469-474.	1.4	36
113	Transgenic Animal Models of Neurodegenerative Diseases. , 2008, , 323-331.		2
114	Biological Transgenic Mouse Models of Alzheimer's Disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2008, 89, 291-301.	1.8	2
115	Processing of Amyloid Precursor Protein and Amyloid Peptide Neurotoxicity. Current Alzheimer Research, 2008, 5, 92-99.	1.4	58

#	ARTICLE	IF	CITATIONS
116	Caspase Activation in Alzheimer's Disease: Early to Rise and Late to Bed. Reviews in the Neurosciences, 2008, 19, 383-93.	2.9	35
117	Reduced Pathology and Improved Behavioral Performance in Alzheimer's Disease Mice Vaccinated With HSV Amplicons Expressing Amyloid- β and Interleukin-4. Molecular Therapy, 2008, 16, 845-853.	8.2	49
118	Coexisting Cholinergic and Parahippocampal Degeneration: A Key to Memory Loss in Dementia and a Challenge for Transgenic Models?. Neurodegenerative Diseases, 2008, 5, 304-317.	1.4	20
119	Potential Mechanisms Linking Cholesterol to Alzheimer's Disease-like Pathology in Rabbit Brain, Hippocampal Organotypic Slices, and Skeletal Muscle. Journal of Alzheimer's Disease, 2008, 15, 673-684.	2.6	60
120	Use of Copper and Insulin-Resistance to Accelerate Cognitive Deficits and Synaptic Protein Loss in a Rat A β -Infusion Alzheimer's Disease Model. Journal of Alzheimer's Disease, 2008, 15, 625-640.	2.6	15
121	Reducing AD-Like Pathology in 3xTg-AD Mouse Model by DNA Epitope Vaccine "A Novel Immunotherapeutic Strategy. PLoS ONE, 2008, 3, e2124.	2.5	100
122	Impaired Adult Neurogenesis in the Dentate Gyrus of a Triple Transgenic Mouse Model of Alzheimer's Disease. PLoS ONE, 2008, 3, e2935.	2.5	314
123	DNA β -Amyloid β 1-42 Trimer Immunization for Alzheimer Disease in a Wild-Type Mouse Model. JAMA - Journal of the American Medical Association, 2009, 302, 1796.	7.4	48
124	Cell Cycle Re-Entry in Alzheimers Disease: A Major Neuropathological Characteristic?. Current Alzheimer Research, 2009, 6, 205-212.	1.4	28
125	Prospects for Early Detection of Alzheimers Disease from Serial MR Images in Transgenic Mouse Models. Current Alzheimer Research, 2009, 6, 503-518.	1.4	15
126	Relevance of Transgenic Mouse Models to Human Alzheimer Disease. Journal of Biological Chemistry, 2009, 284, 6033-6037.	3.4	129
127	Amyloid Reduction by Amyloid- β Vaccination Also Reduces Mouse Tau Pathology and Protects from Neuron Loss in Two Mouse Models of Alzheimer's Disease. Journal of Neuroscience, 2009, 29, 7957-7965.	3.6	85
128	Inhibition of soluble TNF signaling in a mouse model of Alzheimer's disease prevents pre-plaque amyloid-associated neuropathology. Neurobiology of Disease, 2009, 34, 163-177.	4.4	236
129	Brainstem Alzheimer's-like pathology in the triple transgenic mouse model of Alzheimer's disease. Neurobiology of Disease, 2009, 35, 415-425.	4.4	39
130	Protective actions of sex steroid hormones in Alzheimer's disease. Frontiers in Neuroendocrinology, 2009, 30, 239-258.	5.2	424
131	Monitoring the amyloid beta-peptide in vivo "caveat emptor. Drug Discovery Today, 2009, 14, 241-251.	6.4	10
132	Animal models of human amyloidoses: Are transgenic mice worth the time and trouble?. FEBS Letters, 2009, 583, 2663-2673.	2.8	41
133	Triple-transgenic Alzheimer's disease mice exhibit region-specific abnormalities in brain myelination patterns prior to appearance of amyloid and tau pathology. Glia, 2009, 57, 54-65.	4.9	199

#	ARTICLE	IF	CITATIONS
134	Cerebrospinal fluid tau and ptau ₁₈₁ increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer's disease. EMBO Molecular Medicine, 2009, 1, 371-380.	6.9	315
135	Peripherally expressed neprilysin reduces brain amyloid burden: A novel approach for treating Alzheimer's disease. Journal of Neuroscience Research, 2009, 87, 1462-1473.	2.9	70
136	Mechanisms of tau-induced neurodegeneration. Acta Neuropathologica, 2009, 118, 53-69.	7.7	577
137	Intraneuronal pyroglutamate-Aβ ₄₂ triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model. Acta Neuropathologica, 2009, 118, 487-496.	7.7	151
138	Improved Behavioral Response as a Valid Biomarker for Drug Screening Program in Transgenic Rodent Models of Tauopathies. Cellular and Molecular Neurobiology, 2009, 29, 937-944.	3.3	1
139	Neuroinflammation and Memory: The Role of Prostaglandins. Molecular Neurobiology, 2009, 40, 15-32.	4.0	140
140	Immune-Directed Gene Therapeutic Development for Alzheimer's, Prion, and Parkinson's Diseases. Journal of Neuroimmune Pharmacology, 2009, 4, 298-308.	4.1	8
141	Zinc: The brain's dark horse. Synapse, 2009, 63, 1029-1049.	1.2	229
142	Astroglia in dementia and Alzheimer's disease. Cell Death and Differentiation, 2009, 16, 378-385.	11.2	351
143	Quantitation and Mapping of Cerebral Detergent-Insoluble Proteins in the Elderly. Brain Pathology, 2009, 19, 365-374.	4.1	17
144	Genetically Altering Aβ ₂ Distribution from the Brain to the Vasculature Ameliorates Tau Pathology. Brain Pathology, 2009, 19, 421-430.	4.1	33
145	The amyloid hypothesis for Alzheimer's disease: a critical reappraisal. Journal of Neurochemistry, 2009, 110, 1129-1134.	3.9	700
146	Modeling of Alzheimer's disease using viral vectors. Neurochemical Journal, 2009, 3, 253-259.	0.5	0
147	Dissociating Aβ Amyloid from A7 Nicotinic Acetylcholine Receptor by a Novel Therapeutic Agent, S 24795, Normalizes A7 Nicotinic Acetylcholine and NMDA Receptor Function in Alzheimer's Disease Brain. Journal of Neuroscience, 2009, 29, 10961-10973.	3.6	97
148	Prevention of age-associated dementia. Brain Research Bulletin, 2009, 80, 315-325.	3.0	26
149	DNA base excision repair activities in mouse models of Alzheimer's disease. Neurobiology of Aging, 2009, 30, 2080-2081.	3.1	24
150	Sorafenib inhibits nuclear factor kappa B, decreases inducible nitric oxide synthase and cyclooxygenase-2 expression, and restores working memory in APPswe mice. Neuroscience, 2009, 162, 1220-1231.	2.3	64
151	Amyloid-β ₂ expression in retrosplenial cortex of triple transgenic mice: relationship to cholinergic axonal afferents from medial septum. Neuroscience, 2009, 164, 1334-1346.	2.3	16

#	ARTICLE	IF	CITATIONS
152	NAP has no effect on spatial memory after short-term treatment in advanced stage Alzheimer's disease mouse model. <i>Peptides</i> , 2009, 30, 2480-2482.	2.4	1
153	Triple fluorescence labelling of neuronal, glial and vascular markers revealing pathological alterations in various animal models. <i>Journal of Chemical Neuroanatomy</i> , 2009, 37, 128-138.	2.1	26
154	Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 14670-14675.	7.1	791
155	Â-Amyloid Oligomers Induce Phosphorylation of Tau and Inactivation of Insulin Receptor Substrate via c-Jun N-Terminal Kinase Signaling: Suppression by Omega-3 Fatty Acids and Curcumin. <i>Journal of Neuroscience</i> , 2009, 29, 9078-9089.	3.6	474
156	Cerebral amyloid angiopathy in the aetiology and immunotherapy of Alzheimer disease. <i>Alzheimer's Research and Therapy</i> , 2009, 1, 6.	6.2	116
157	Interferon-Î³ Differentially Affects Alzheimer's Disease Pathologies and Induces Neurogenesis in Triple Transgenic-AD Mice. <i>American Journal of Pathology</i> , 2009, 175, 2076-2088.	3.8	92
158	Generating Differentially Targeted Amyloid-Î² Specific Intrabodies as a Passive Vaccination Strategy for Alzheimer's Disease. <i>Molecular Therapy</i> , 2009, 17, 2031-2040.	8.2	43
159	The Acyl-Coenzyme A: Cholesterol Acyltransferase Inhibitor CI-1011 Reverses Diffuse Brain Amyloid Pathology in Aged Amyloid Precursor Protein Transgenic Mice. <i>Journal of Neuropathology and Experimental Neurology</i> , 2010, 69, 777-788.	1.7	50
160	Amyloid-Î² Peptides Stimulate the Expression of the p75NTR Neurotrophin Receptor in SHSY5Y Human Neuroblastoma Cells and AD Transgenic Mice. <i>Journal of Alzheimer's Disease</i> , 2010, 19, 915-925.	2.6	76
161	Preparation and Characterization of Neurotoxic Tau Oligomers. <i>Biochemistry</i> , 2010, 49, 10039-10041.	2.5	302
162	Beta amyloid peptide: from different aggregation forms to the activation of different biochemical pathways. <i>European Biophysics Journal</i> , 2010, 39, 877-888.	2.2	49
163	APP transgenic modeling of Alzheimer's disease: mechanisms of neurodegeneration and aberrant neurogenesis. <i>Brain Structure and Function</i> , 2010, 214, 111-126.	2.3	92
164	Understanding the molecular basis of Alzheimer's disease using a <i>Caenorhabditis elegans</i> model system. <i>Brain Structure and Function</i> , 2010, 214, 263-283.	2.3	56
165	Immunotherapeutic approaches for Alzheimer's disease in transgenic mouse models. <i>Brain Structure and Function</i> , 2010, 214, 201-218.	2.3	36
166	Alzheimer's Disease and Neuronal Network Activity. <i>NeuroMolecular Medicine</i> , 2010, 12, 44-47.	3.4	26
167	Convergence of Amyloid-Î² and Tau Pathologies on Mitochondria In Vivo. <i>Molecular Neurobiology</i> , 2010, 41, 107-114.	4.0	144
168	Profile for Amyloid-Î² and Tau Expression in Primary Cortical Cultures from 3xTg-AD Mice. <i>Cellular and Molecular Neurobiology</i> , 2010, 30, 577-590.	3.3	36
169	Searching for new animal models of Alzheimer's disease. <i>European Journal of Pharmacology</i> , 2010, 626, 57-63.	3.5	44

#	ARTICLE	IF	CITATIONS
170	Characterization of the 3xTg-AD mouse model of Alzheimer's disease: Part 1. Circadian changes. Brain Research, 2010, 1348, 139-148.	2.2	161
171	Regional cerebral glucose uptake in the 3xTG model of Alzheimer's disease highlights common regional vulnerability across AD mouse models. Brain Research, 2010, 1347, 179-185.	2.2	92
172	Characterization of the 3xTg-AD mouse model of Alzheimer's disease: Part 2. Behavioral and cognitive changes. Brain Research, 2010, 1348, 149-155.	2.2	182
173	Testosterone regulation of Alzheimer-like neuropathology in male 3xTg-AD mice involves both estrogen and androgen pathways. Brain Research, 2010, 1359, 281-290.	2.2	98
174	Neuronal nicotinic acetylcholine receptor-cholesterol crosstalk in Alzheimer's disease. FEBS Letters, 2010, 584, 1856-1863.	2.8	49
175	Concomitant astroglial atrophy and astrogliosis in a triple transgenic animal model of Alzheimer's disease. Glia, 2010, 58, 831-838.	4.9	385
177	Olfactory epithelium amyloid β and paired helical filament τ pathology in Alzheimer disease. Annals of Neurology, 2010, 67, 462-469.	5.3	167
178	Secreted amyloid precursor protein and holo α APP bind amyloid β through distinct domains eliciting different toxic responses on hippocampal neurons. Journal of Neuroscience Research, 2010, 88, 1795-1803.	2.9	13
179	Antidepressants are a rational complementary therapy for the treatment of Alzheimer's disease. Molecular Neurodegeneration, 2010, 5, 10.	10.8	45
180	Age-dependent changes in TDP-43 levels in a mouse model of Alzheimer disease are linked to A β oligomers accumulation. Molecular Neurodegeneration, 2010, 5, 51.	10.8	30
181	Tyrosine phosphorylation of tau accompanies disease progression in transgenic mouse models of tauopathy. Neuropathology and Applied Neurobiology, 2010, 36, 462-477.	3.2	63
182	<i>In vivo</i> labelling of hippocampal β -amyloid in triple α transgenic mice with a fluorescent acetylcholinesterase inhibitor released from nanoparticles. European Journal of Neuroscience, 2010, 31, 99-109.	2.6	23
183	Serotonin fibre sprouting and increase in serotonin transporter immunoreactivity in the CA1 area of hippocampus in a triple transgenic mouse model of Alzheimer's disease. European Journal of Neuroscience, 2010, 32, 71-79.	2.6	32
184	Widespread deficits in adult neurogenesis precede plaque and tangle formation in the 3xTg mouse model of Alzheimer's disease. European Journal of Neuroscience, 2010, 32, 905-920.	2.6	98
185	The relationship between parkin and protein aggregation in neurodegenerative diseases. Frontiers in Psychiatry, 2010, 1, 15.	2.6	17
186	Neocortical Variation of A β Load in Fully Expressed, Pure Alzheimer's Disease. Journal of Alzheimer's Disease, 2010, 19, 57-68.	2.6	19
187	Gender-Specific Neuroimmunoendocrine Response to Treadmill Exercise in 3xTg-AD Mice. International Journal of Alzheimer's Disease, 2010, 2010, 1-17.	2.0	67
188	Pathological Hallmarks, Clinical Parallels, and Value for Drug Testing in Alzheimer's Disease of the APP[V717I] London Transgenic Mouse Model. International Journal of Alzheimer's Disease, 2010, 2010, 1-9.	2.0	20

#	ARTICLE	IF	CITATIONS
189	Staging of Alzheimer's Pathology in Triple Transgenic Mice: A Light and Electron Microscopic Analysis. International Journal of Alzheimer's Disease, 2010, 2010, 1-24.	2.0	59
190	The Society for Neuroscience 2009 Meeting Report, Part 4. Journal of Alzheimer's Disease, 2010, 20, 673-679.	2.6	0
191	Animal Models of Neurological Disease. Advances in Experimental Medicine and Biology, 2010, 671, 23-40.	1.6	8
192	L-3-n-Butylphthalide Improves Cognitive Impairment and Reduces Amyloid- β in a Transgenic Model of Alzheimer's Disease. Journal of Neuroscience, 2010, 30, 8180-8189.	3.6	122
193	Effect of Huprine X on β -Amyloid, Synaptophysin and α 7 Neuronal Nicotinic Acetylcholine Receptors in the Brain of 3xTg-AD and APPswe Transgenic Mice. Neurodegenerative Diseases, 2010, 7, 379-388.	1.4	31
194	Tumor Necrosis Factor- α (TNF- α) Regulates Shedding of TNF- α Receptor 1 by the Metalloprotease-Disintegrin ADAM8: Evidence for a Protease-Regulated Feedback Loop in Neuroprotection. Journal of Neuroscience, 2010, 30, 12210-12218.	3.6	62
195	Tau-tubulin kinase 1 enhances prefibrillar tau aggregation and motor neuron degeneration in P301L FTDP-tau mutant mice. FASEB Journal, 2010, 24, 2904-2915.	0.5	32
196	Blocking ADAM10 synaptic trafficking generates a model of sporadic Alzheimer's disease. Brain, 2010, 133, 3323-3335.	7.6	71
197	Neurogenesis and Alzheimers Disease: Biology and Pathophysiology in Mice and Men. Current Alzheimer Research, 2010, 7, 113-125.	1.4	80
198	Possible Role of Tau in Mediating Pathological Effects of apoE4 in vivo prior to and following Activation of the Amyloid Cascade. Neurodegenerative Diseases, 2010, 7, 16-23.	1.4	16
199	Dietary zinc supplementation of 3xTg-AD mice increases BDNF levels and prevents cognitive deficits as well as mitochondrial dysfunction. Cell Death and Disease, 2010, 1, e91-e91.	6.3	162
200	The Achilles heel of β -secretase: can we contain Alzheimer's disease by reducing synthesis of β -amyloid?. Acta Pharmacologica Sinica, 2010, 31, 1407-1408.	6.1	0
201	Alterations of brain and cerebellar proteomes linked to β and tau pathology in a female triple-transgenic murine model of Alzheimer's disease. Cell Death and Disease, 2010, 1, e90-e90.	6.3	51
202	Increase in the density of resting microglia precedes neuritic plaque formation and microglial activation in a transgenic model of Alzheimer's disease. Cell Death and Disease, 2010, 1, e1-e1.	6.3	91
203	Insights from <i>Drosophila</i> models of Alzheimer's disease. Biochemical Society Transactions, 2010, 38, 988-992.	3.4	24
204	Small Molecule Microarrays Enable the Discovery of Compounds That Bind the Alzheimer's β Peptide and Reduce its Cytotoxicity. Journal of the American Chemical Society, 2010, 132, 17015-17022.	13.7	80
205	A NH2 Tau Fragment Targets Neuronal Mitochondria at AD Synapses: Possible Implications for Neurodegeneration. Journal of Alzheimer's Disease, 2010, 21, 445-470.	2.6	92
206	EEG, Activity, and Sleep Architecture in a Transgenic β PPswe/PSEN1A246E Alzheimer's Disease Mouse. Journal of Alzheimer's Disease, 2010, 22, 873-887.	2.6	92

#	ARTICLE	IF	CITATIONS
207	Animal models reveal role for tau phosphorylation in human disease. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2010, 1802, 860-871.	3.8	67
208	Murine models of Alzheimer's disease and their use in developing immunotherapies. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2010, 1802, 847-859.	3.8	71
209	Experience-dependent regulation of vesicular zinc in male and female 3xTg-AD mice. <i>Neurobiology of Aging</i> , 2010, 31, 605-613.	3.1	14
210	High-fat diet aggravates amyloid-beta and tau pathologies in the 3xTg-AD mouse model. <i>Neurobiology of Aging</i> , 2010, 31, 1516-1531.	3.1	241
211	The role of caspases in Alzheimer's disease; potential novel therapeutic opportunities. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2010, 15, 1403-1409.	4.9	101
212	Neurogenesis and Alzheimer's disease: At the crossroads. <i>Experimental Neurology</i> , 2010, 223, 267-281.	4.1	259
213	Signaling effect of amyloid- β 42 on the processing of A β PP. <i>Experimental Neurology</i> , 2010, 221, 18-25.	4.1	51
214	A β exacerbates the neuronal dysfunction caused by human tau expression in a <i>Drosophila</i> model of Alzheimer's disease. <i>Experimental Neurology</i> , 2010, 223, 401-409.	4.1	81
215	Memantine Improves Cognition and Reduces Alzheimer's-Like Neuropathology in Transgenic Mice. <i>American Journal of Pathology</i> , 2010, 176, 870-880.	3.8	188
216	Early Oligodendrocyte/Myelin Pathology in Alzheimer's Disease Mice Constitutes a Novel Therapeutic Target. <i>American Journal of Pathology</i> , 2010, 177, 1422-1435.	3.8	178
217	A β Accelerates the Spatiotemporal Progression of Tau Pathology and Augments Tau Amyloidosis in an Alzheimer Mouse Model. <i>American Journal of Pathology</i> , 2010, 177, 1977-1988.	3.8	179
218	Braak Staging in Mouse Models of Alzheimer's Disease. <i>American Journal of Pathology</i> , 2010, 177, 1603-1605.	3.8	7
219	Molecular Interplay between Mammalian Target of Rapamycin (mTOR), Amyloid- β , and Tau. <i>Journal of Biological Chemistry</i> , 2010, 285, 13107-13120.	3.4	754
220	Diabetes, Insulin and Alzheimer's Disease. <i>Research and Perspectives in Alzheimer's Disease</i> , 2010, , .	0.1	7
221	Neurochemical Aspects of Neurotraumatic and Neurodegenerative Diseases. , 2010, , .		87
222	β -Amyloid1 β 42 Gene Transfer Model Exhibits Intraneuronal Amyloid, Gliosis, Tau Phosphorylation, and Neuronal Loss. <i>Journal of Biological Chemistry</i> , 2010, 285, 7440-7446.	3.4	53
223	Synergistic Interactions between Repeats in Tau Protein and A β Amyloids May Be Responsible for Accelerated Aggregation via Polymorphic States. <i>Biochemistry</i> , 2011, 50, 5172-5181.	2.5	95
224	Mutations That Replace Aromatic Side Chains Promote Aggregation of the Alzheimer's A β Peptide. <i>Biochemistry</i> , 2011, 50, 4058-4067.	2.5	55

#	ARTICLE	IF	CITATIONS
225	Amyloid Precursor Protein Processing and Alzheimer's Disease. Annual Review of Neuroscience, 2011, 34, 185-204.	10.7	1,455
227	The Mitochondria-Targeted Antioxidant MitoQ Prevents Loss of Spatial Memory Retention and Early Neuropathology in a Transgenic Mouse Model of Alzheimer's Disease. Journal of Neuroscience, 2011, 31, 15703-15715.	3.6	354
228	Using Positron Emission Tomography and Florbetapir F 18 to Image Cortical Amyloid in Patients With Mild Cognitive Impairment or Dementia Due to Alzheimer Disease. Archives of Neurology, 2011, 68, 1404.	4.5	310
229	Physical Exercise Protects Against Alzheimer's Disease in 3xTg-AD Mice. Journal of Alzheimer's Disease, 2011, 24, 421-454.	2.6	223
230	Ablation of TNF-RI/RII Expression in Alzheimer's Disease Mice Leads to an Unexpected Enhancement of Pathology. American Journal of Pathology, 2011, 179, 2053-2070.	3.8	91
231	Calcium channel blocking as a therapeutic strategy for Alzheimer's disease: The case for isradipine. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2011, 1812, 1584-1590.	3.8	114
232	The cholinergic system in aging and neuronal degeneration. Behavioural Brain Research, 2011, 221, 555-563.	2.2	863
233	Behavioural and cellular effects of exogenous amyloid- β peptides in rodents. Behavioural Brain Research, 2011, 225, 623-641.	2.2	45
234	Development of Alzheimer-disease neuroimaging-biomarkers using mouse models with amyloid-precursor protein-transgene expression. Progress in Neurobiology, 2011, 95, 547-556.	5.7	30
235	β -Amyloid impairs axonal BDNF retrograde trafficking. Neurobiology of Aging, 2011, 32, 821-833.	3.1	163
236	Endogenous $A\beta$ causes cell death via early tau hyperphosphorylation. Neurobiology of Aging, 2011, 32, 969-990.	3.1	61
237	Insights from Caenorhabditis elegans on the role of metals in neurodegenerative diseases. Metallomics, 2011, 3, 271.	2.4	38
238	The Role of Tau in Alzheimer's Disease and Related Disorders. CNS Neuroscience and Therapeutics, 2011, 17, 514-524.	3.9	195
239	Yeast as a Model System to Study Tau Biology. International Journal of Alzheimer's Disease, 2011, 2011, 1-16.	2.0	25
240	Comparison of Vascular Perturbations in an $A\beta$ -Injected Animal Model and in AD Brain. International Journal of Alzheimer's Disease, 2011, 2011, 1-8.	2.0	28
241	Brain-Reactive Autoantibodies Prevalent in Human Sera Increase Intraneuronal Amyloid- β 1-42 Deposition. Journal of Alzheimer's Disease, 2011, 25, 605-622.	2.6	65
242	DHA Improves Cognition and Prevents Dysfunction of Entorhinal Cortex Neurons in 3xTg-AD Mice. PLoS ONE, 2011, 6, e17397.	2.5	148
243	Voluntary Running and Environmental Enrichment Restores Impaired Hippocampal Neurogenesis in a Triple Transgenic Mouse Model of Alzheimers Disease. Current Alzheimer Research, 2011, 8, 707-717.	1.4	88

#	ARTICLE	IF	CITATIONS
244	Effect of Environmental Enrichment on the Immunoendocrine Aging of Male and Female Triple-Transgenic 3xTg-AD Mice for Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2011, 25, 727-737.	2.6	37
245	Endogenous Conversion of Omega-6 into Omega-3 Fatty Acids Improves Neuropathology in an Animal Model of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2011, 27, 853-869.	2.6	66
246	Targeting the Kynurenine Pathway-Related Alterations in Alzheimer's Disease: A Future Therapeutic Strategy. <i>Journal of Alzheimer's Disease</i> , 2011, 24, 199-209.	2.6	26
247	Biochemical and Morphological Characterization of the A β 2PP/PS/Tau Triple Transgenic Mouse Model and Its Relevance to Sporadic Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2011, 27, 361-376.	2.6	18
248	Genetic strategies to study TDP-43 in rodents and to develop preclinical therapeutics for amyotrophic lateral sclerosis. <i>European Journal of Neuroscience</i> , 2011, 34, 1179-1188.	2.6	16
249	Animal models in the drug discovery pipeline for Alzheimer's disease. <i>British Journal of Pharmacology</i> , 2011, 164, 1285-1300.	5.4	180
250	Neurogenesis in Alzheimer's disease. <i>Journal of Anatomy</i> , 2011, 219, 78-89.	1.5	117
251	Cholinergic basal forebrain system alterations in 3xTg-AD transgenic mice. <i>Neurobiology of Disease</i> , 2011, 41, 338-352.	4.4	77
252	Morin attenuates tau hyperphosphorylation by inhibiting GSK3 β . <i>Neurobiology of Disease</i> , 2011, 44, 223-230.	4.4	87
253	Brain-derived neurotrophic factor: the link between amyloid- β and memory loss. <i>Future Neurology</i> , 2011, 6, 627-639.	0.5	48
254	Validation of a rodent model of episodic memory. <i>Animal Cognition</i> , 2011, 14, 325-340.	1.8	42
255	Transgenic animal models of neurodegeneration based on human genetic studies. <i>Journal of Neural Transmission</i> , 2011, 118, 27-45.	2.8	38
256	The β -Secretase Modulator CHF5074 Reduces the Accumulation of Native Hyperphosphorylated Tau in a Transgenic Mouse Model of Alzheimer's Disease. <i>Journal of Molecular Neuroscience</i> , 2011, 45, 22-31.	2.3	25
257	Neuroglial Roots of Neurodegenerative Diseases?. <i>Molecular Neurobiology</i> , 2011, 43, 87-96.	4.0	67
258	Age-dependent decrease in glutamine synthetase expression in the hippocampal astroglia of the triple transgenic Alzheimer's disease mouse model: mechanism for deficient glutamatergic transmission?. <i>Molecular Neurodegeneration</i> , 2011, 6, 55.	10.8	164
259	ST101 induces a novel 17kDa APP cleavage that precludes A β generation in vivo. <i>Annals of Neurology</i> , 2011, 69, 831-844.	5.3	32
260	An Alzheimer's disease-relevant presenilin-1 mutation augments amyloid- β -induced oligodendrocyte dysfunction. <i>Glia</i> , 2011, 59, 627-640.	4.9	52
261	Early dysregulation of the mitochondrial proteome in a mouse model of Alzheimer's disease. <i>Journal of Proteomics</i> , 2011, 74, 466-479.	2.4	113

#	ARTICLE	IF	CITATIONS
262	Genetic Mouse Models of Neurodegenerative Diseases. Progress in Molecular Biology and Translational Science, 2011, 100, 419-482.	1.7	37
263	The “Aged Garlic Extract” (AGE) and One of its Active Ingredients S-Allyl-LCysteine (SAC) as Potential Preventive and Therapeutic Agents for Alzheimer's Disease (AD). Current Medicinal Chemistry, 2011, 18, 3306-3313.	2.4	93
264	Modulating Alzheimer's Disease Through Caffeine: A Putative Link to Epigenetics. Journal of Alzheimer's Disease, 2011, 24, 161-171.	2.6	70
265	The ER stress factor XBP1s prevents amyloid- β^2 neurotoxicity. Human Molecular Genetics, 2011, 20, 2144-2160.	2.9	258
266	Impaired Attention in the 3xTgAD Mouse Model of Alzheimer's Disease: Rescue by Donepezil (Aricept). Journal of Neuroscience, 2011, 31, 3500-3507.	3.6	138
267	A translational continuum of model systems for evaluating treatment strategies in Alzheimer's disease: isradipine as a candidate drug. DMM Disease Models and Mechanisms, 2011, 4, 634-648.	2.4	39
268	Early Astrocytic Atrophy in the Entorhinal Cortex of a Triple Transgenic Animal Model of Alzheimer's Disease. ASN Neuro, 2011, 3, AN20110025.	2.7	170
269	CREB-activity and nmnat2 transcription are down-regulated prior to neurodegeneration, while NMNAT2 over-expression is neuroprotective, in a mouse model of human tauopathy. Human Molecular Genetics, 2012, 21, 251-267.	2.9	98
270	Restoration of dopamine release deficits during object recognition memory acquisition attenuates cognitive impairment in a triple transgenic mice model of Alzheimer's disease. Learning and Memory, 2012, 19, 453-460.	1.3	106
271	Allopregnanolone Increases the Number of Dopaminergic Neurons in Substantia Nigra of a Triple Transgenic Mouse Model of Alzheimer's Disease. Current Alzheimer Research, 2012, 9, 473-480.	1.4	41
272	Striatal-Enriched Protein Tyrosine Phosphatase in Alzheimer's Disease. Advances in Pharmacology, 2012, 64, 303-325.	2.0	20
273	A Reversible Early Oxidized Redox State That Precedes Macromolecular ROS Damage in Aging Nontransgenic and 3xTg-AD Mouse Neurons. Journal of Neuroscience, 2012, 32, 5821-5832.	3.6	111
274	Early Increases in Soluble Amyloid- β^2 Levels Coincide with Cholinergic Degeneration in 3xTg-AD Mice. Journal of Alzheimer's Disease, 2012, 32, 267-272.	2.6	15
275	Stimulation of autophagy reduces neurodegeneration in a mouse model of human tauopathy. Brain, 2012, 135, 2169-2177.	7.6	291
276	Transgenic Mouse Models of Alzheimer Disease: Developing a Better Model as a Tool for Therapeutic Interventions. Current Pharmaceutical Design, 2012, 18, 1131-1147.	1.9	146
277	Diminished Parkin Solubility and Co-Localization with Intraneuronal Amyloid- β^2 are Associated with Autophagic Defects in Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 33, 231-247.	2.6	76
278	Role of Tau Protein in Neuronal Damage in Alzheimer's Disease and Down Syndrome. Archives of Medical Research, 2012, 43, 645-654.	3.3	54
279	Alzheimer's Disease and Amyloid: Culprit or Coincidence?. International Review of Neurobiology, 2012, 102, 277-316.	2.0	67

#	ARTICLE	IF	CITATIONS
280	Ergothioneine protects against neuronal injury induced by $A\beta$ -amyloid in mice. Food and Chemical Toxicology, 2012, 50, 3902-3911.	3.6	82
281	Effects of the Superoxide Dismutase/Catalase Mimetic EUK-207 in a Mouse Model of Alzheimer's Disease: Protection Against and Interruption of Progression of Amyloid and Tau Pathology and Cognitive Decline. Journal of Alzheimer's Disease, 2012, 30, 183-208.	2.6	58
282	Animal Models of Alzheimer Disease. Cold Spring Harbor Perspectives in Medicine, 2012, 2, a006320-a006320.	6.2	336
283	Hypermetabolism in a triple-transgenic mouse model of Alzheimer's disease. Neurobiology of Aging, 2012, 33, 187-193.	3.1	46
284	Mitochondrial base excision repair in mouse synaptosomes during normal aging and in a model of Alzheimer's disease. Neurobiology of Aging, 2012, 33, 694-707.	3.1	32
285	Fyn knock-down increases $A\beta$, decreases phospho-tau, and worsens spatial learning in 3xTg-AD mice. Neurobiology of Aging, 2012, 33, 825.e15-825.e24.	3.1	21
286	Allopregnanolone restores hippocampal-dependent learning and memory and neural progenitor survival in aging 3xTgAD and nonTg mice. Neurobiology of Aging, 2012, 33, 1493-1506.	3.1	128
287	Interaction between NH ₂ -tau fragment and $A\beta$ in Alzheimer's disease mitochondria contributes to the synaptic deterioration. Neurobiology of Aging, 2012, 33, 833.e1-833.e25.	3.1	78
288	Glutamatergic alterations and mitochondrial impairment in a murine model of Alzheimer disease. Neurobiology of Aging, 2012, 33, 1121.e1-1121.e12.	3.1	79
289	Targeting Synaptic Dysfunction in Alzheimer's Disease Therapy. Molecular Neurobiology, 2012, 46, 572-587.	4.0	80
290	Astrocytic cytoskeletal atrophy in the medial prefrontal cortex of a triple transgenic mouse model of Alzheimer's disease. Journal of Anatomy, 2012, 221, 252-262.	1.5	131
291	Rac1b Increases with Progressive Tau Pathology within Cholinergic Nucleus Basalis Neurons in Alzheimer's Disease. American Journal of Pathology, 2012, 180, 526-540.	3.8	30
292	Mouse models of Alzheimer's disease. Brain Research Bulletin, 2012, 88, 3-12.	3.0	254
293	Early intervention with a small molecule inhibitor for tumor necrosis factor- α prevents cognitive deficits in a triple transgenic mouse model of Alzheimer's disease. Journal of Neuroinflammation, 2012, 9, 99.	7.2	79
294	Alzheimer's disease: biological aspects, therapeutic perspectives and diagnostic tools. Journal of Physics Condensed Matter, 2012, 24, 244102.	1.8	51
295	Active DNA $A\beta$ vaccination as immunotherapy for Alzheimer disease. Translational Neuroscience, 2012, 3, 307-313.	1.4	20
296	Cognitive and non-cognitive behaviors in the triple transgenic mouse model of Alzheimer's disease expressing mutated APP, PS1, and Mapt (3xTg-AD). Behavioural Brain Research, 2012, 234, 334-342.	2.2	118
297	Reduction of the immunostainable length of the hippocampal dentate granule cells' primary cilia in 3xAD-transgenic mice producing human $A\beta$ 1-42 and tau. Biochemical and Biophysical Research Communications, 2012, 427, 218-222.	2.1	35

#	ARTICLE	IF	CITATIONS
298	Parkin prevents cortical atrophy and A β ² -induced alterations of brain metabolism: 13C NMR and magnetic resonance imaging studies in AD models. <i>Neuroscience</i> , 2012, 225, 22-34.	2.3	22
299	The serotonergic system in ageing and Alzheimer's disease. <i>Progress in Neurobiology</i> , 2012, 99, 15-41.	5.7	211
300	Evidence for the accumulation of Abeta immunoreactive material in the human brain and in transgenic animal models. <i>Life Sciences</i> , 2012, 91, 1141-1147.	4.3	13
301	scyllo-Inositol, Preclinical, and Clinical Data for Alzheimer's Disease. <i>Advances in Pharmacology</i> , 2012, 64, 177-212.	2.0	61
302	Phytochemicals, Signal Transduction, and Neurological Disorders. , 2012, , .		33
303	Elucidating the Triggers, Progression, and Effects of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2012, 33, S195-S210.	2.6	16
304	GFAP Isoforms in Adult Mouse Brain with a Focus on Neurogenic Astrocytes and Reactive Astrogliosis in Mouse Models of Alzheimer Disease. <i>PLoS ONE</i> , 2012, 7, e42823.	2.5	246
305	Brain Gene Expression of a Sporadic (icv-STZ Mouse) and a Familial Mouse Model (3xTg-AD Mouse) of Alzheimer's Disease. <i>PLoS ONE</i> , 2012, 7, e51432.	2.5	47
306	Neuroregenerative Mechanisms of Allopregnanolone in Alzheimer's Disease. <i>Frontiers in Endocrinology</i> , 2011, 2, 117.	3.5	38
307	Neuroprotective Effects of Neuropeptide Y and Y2 and Y5 Receptor Agonists In Vitro and In Vivo. , 2012, , .		0
308	Dietary Supplementation with S-Adenosyl Methionine Delayed Amyloid- β ² and Tau Pathology in 3xTg-AD Mice. <i>Journal of Alzheimer's Disease</i> , 2012, 28, 423-431.	2.6	58
309	The role of mTOR signaling in Alzheimer disease. <i>Frontiers in Bioscience - Scholar</i> , 2012, S4, 941-952.	2.1	185
310	Amyloid beta peptide 1-42 disturbs intracellular calcium homeostasis through activation of GluN2B-containing N-methyl-d-aspartate receptors in cortical cultures. <i>Cell Calcium</i> , 2012, 51, 95-106.	2.4	160
311	Time sequence of oxidative stress in the brain from transgenic mouse models of Alzheimer's disease related to the amyloid- β ² cascade. <i>Free Radical Biology and Medicine</i> , 2012, 52, 593-600.	2.9	41
312	Membrane Trafficking Pathways in Alzheimer's Disease. <i>Traffic</i> , 2012, 13, 759-770.	2.7	181
313	Peripheral immune system and neuroimmune communication impairment in a mouse model of Alzheimer's disease. <i>Annals of the New York Academy of Sciences</i> , 2012, 1262, 74-84.	3.8	46
314	Dysfunction of TGF- β ¹ signaling in Alzheimer's disease: perspectives for neuroprotection. <i>Cell and Tissue Research</i> , 2012, 347, 291-301.	2.9	96
315	Tackling neurodegenerative diseases: animal models of Alzheimer's disease and Parkinson's disease. <i>Genes and Genomics</i> , 2013, 35, 425-440.	1.4	10

#	ARTICLE	IF	CITATIONS
316	Age-dependent changes in hippocampal synaptic transmission and plasticity in the PLB1Triple Alzheimer mouse. Cellular and Molecular Life Sciences, 2013, 70, 2585-2601.	5.4	20
317	Spatial learning impairments in PLB1Triple knock-in Alzheimer mice are task-specific and age-dependent. Cellular and Molecular Life Sciences, 2013, 70, 2603-2619.	5.4	25
318	Neurogenesis and Neural Plasticity. Current Topics in Behavioral Neurosciences, 2013, , .	1.7	7
319	Viewpoint: Crosstalks between neurofibrillary tangles and amyloid plaque formation. Ageing Research Reviews, 2013, 12, 174-181.	10.9	35
320	Transcriptome meta-analysis reveals a central role for sex steroids in the degeneration of hippocampal neurons in Alzheimer's disease. BMC Systems Biology, 2013, 7, 51.	3.0	39
321	Nonhuman Amyloid Oligomer Epitope Reduces Alzheimer's-Like Neuropathology in 3xTg-AD Transgenic Mice. Molecular Neurobiology, 2013, 48, 931-940.	4.0	11
322	Chronic Neuron- and Age-Selective Down-Regulation of TNF Receptor Expression in Triple-Transgenic Alzheimer Disease Mice Leads to Significant Modulation of Amyloid- and Tau-Related Pathologies. American Journal of Pathology, 2013, 182, 2285-2297.	3.8	44
323	Glutamine synthetase in astrocytes from entorhinal cortex of the triple transgenic animal model of Alzheimer's disease is not affected by pathological progression. Biogerontology, 2013, 14, 777-787.	3.9	26
324	Biomarker Modeling of Alzheimer's Disease. Neuron, 2013, 80, 1347-1358.	8.1	773
325	Tyrosine kinase inhibition increases functional parkin's interaction and enhances amyloid clearance and cognitive performance. EMBO Molecular Medicine, 2013, 5, 1247-1262.	6.9	122
326	The function of BMP4 during neurogenesis in the adult hippocampus in Alzheimer's disease. Ageing Research Reviews, 2013, 12, 157-164.	10.9	23
327	Hyperglycemia-Induced Tau Cleavage in vitro and in vivo: A Possible Link Between Diabetes and Alzheimer's Disease. Journal of Alzheimer's Disease, 2013, 34, 727-739.	2.6	64
328	Age-related loss of noradrenergic neurons in the brains of triple transgenic mice. Age, 2013, 35, 139-147.	3.0	43
329	Morphological analysis of the hippocampal region associated with an innate behaviour task in the transgenic mouse model (3xTg-AD) for Alzheimer disease. Neurologia (English Edition), 2013, 28, 497-502.	0.4	9
330	Maternal genotype influences behavioral development of 3xTg-AD mouse pups. Behavioural Brain Research, 2013, 252, 40-48.	2.2	21
331	Mifepristone Alters Amyloid Precursor Protein Processing to Preclude Amyloid Beta and Also Reduces Tau Pathology. Biological Psychiatry, 2013, 74, 357-366.	1.3	87
332	Tauroursodeoxycholic acid (TUDCA) supplementation prevents cognitive impairment and amyloid deposition in APP/PS1 mice. Neurobiology of Disease, 2013, 50, 21-29.	4.4	93
334	Cellular prion protein modulates A β -amyloid deposition in aged APP/PS1 transgenic mice. Neurobiology of Aging, 2013, 34, 2793-2804.	3.1	17

#	ARTICLE	IF	CITATIONS
335	Disruption of neocortical histone H3 homeostasis by soluble A β : implications for Alzheimer's disease. <i>Neurobiology of Aging</i> , 2013, 34, 2081-2090.	3.1	56
336	Nicotinamide riboside restores cognition through an upregulation of proliferator-activated receptor- β coactivator 1 α regulated β -secretase 1 degradation and mitochondrial gene expression in Alzheimer's mouse models. <i>Neurobiology of Aging</i> , 2013, 34, 1581-1588.	3.1	287
337	Sex Steroid Levels and α -Synuclein Pathology in 3xTg-AD Mice. <i>Journal of Neuroendocrinology</i> , 2013, 25, 131-144.	2.6	34
338	Reduced amyloid β degradation in early α -Synuclein Alzheimer's disease but not in the α -Synuclein APP β PS1dE9 and 3xTg-AD mouse models. <i>Aging Cell</i> , 2013, 12, 499-507.	6.7	53
339	Establishment of experimental models for Alzheimer's disease research. <i>International Journal of Neuroscience</i> , 2013, 123, 823-831.	1.6	7
340	Synthesis, biological evaluation and molecular modeling of substituted 2-aminobenzimidazoles as novel inhibitors of acetylcholinesterase and butyrylcholinesterase. <i>Bioorganic and Medicinal Chemistry</i> , 2013, 21, 4218-4224.	3.0	43
341	Ligand for Translocator Protein Reverses Pathology in a Mouse Model of Alzheimer's Disease. <i>Journal of Neuroscience</i> , 2013, 33, 8891-8897.	3.6	125
342	Systemic effects of Wnt signaling. <i>Journal of Cellular Physiology</i> , 2013, 228, 1428-1432.	4.1	45
343	Exogenous galanin attenuates spatial memory impairment and decreases hippocampal beta-amyloid levels in rat model of Alzheimer's disease. <i>International Journal of Neuroscience</i> , 2013, 123, 759-765.	1.6	22
344	Synchrotron FTIR reveals lipid around and within amyloid plaques in transgenic mice and Alzheimer's disease brain. <i>Analyst</i> , 2013, 138, 3991.	3.5	75
345	PAK Inactivation Impairs Social Recognition in 3xTg-AD Mice without Increasing Brain Deposition of Tau and A β . <i>Journal of Neuroscience</i> , 2013, 33, 10729-10740.	3.6	34
346	A Non-transgenic Mouse Model (icv-STZ Mouse) of Alzheimer's Disease: Similarities to and Differences from the Transgenic Model (3xTg-AD Mouse). <i>Molecular Neurobiology</i> , 2013, 47, 711-725.	4.0	226
347	Nanoparticulates. , 2013, , 1373-1419.		5
348	Protein restriction cycles reduce α -Synuclein and phosphorylated Tau, and improve behavioral performance in an Alzheimer's disease mouse model. <i>Aging Cell</i> , 2013, 12, 257-268.	6.7	71
349	Prolonged Running, not Fluoxetine Treatment, Increases Neurogenesis, but does not Alter Neuropathology, in the 3xTg Mouse Model of Alzheimer's Disease. <i>Current Topics in Behavioral Neurosciences</i> , 2013, 15, 313-340.	1.7	85
350	Beneficial Effects of Curcumin on Neurological Disorders. , 2013, , 151-197.		2
351	Astrocytes and Glutamate Homeostasis in Alzheimer's Disease: A Decrease in Glutamine Synthetase, But Not in Glutamate Transporter-1, in the Prefrontal Cortex. <i>ASN Neuro</i> , 2013, 5, AN20130017.	2.7	100
352	Proteolytic Cleavage of Polymeric Tau Protein by Caspase-3: Implications for Alzheimer Disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 2013, 72, 1145-1161.	1.7	43

#	ARTICLE	IF	CITATIONS
353	Is Alzheimer's a disease of the white matter?. Current Opinion in Psychiatry, 2013, 26, 244-251.	6.3	110
354	Early intervention in the 3xTg-AD mice with an amyloid β -antibody fragment ameliorates first hallmarks of Alzheimer disease. MAbs, 2013, 5, 665-864.	5.2	48
355	Molecular Differences and Similarities between Alzheimer's Disease and the 5XFAD Transgenic Mouse Model of Amyloidosis. Biochemistry Insights, 2013, 6, BCI.S13025.	3.3	48
356	Loss of deep cerebellar nuclei neurons in the 3xTg-AD mice and protection by an anti-amyloid β antibody fragment. MAbs, 2013, 5, 660-664.	5.2	24
358	Anti-amyloid-beta to tau-based immunization: developments in immunotherapy for Alzheimer's disease. ImmunoTargets and Therapy, 2013, 2013, 105.	5.8	32
359	An Update of Animal Models of Alzheimer Disease with a Reevaluation of Plaque Depositions. Experimental Neurobiology, 2013, 22, 84-95.	1.6	83
360	Sex-Specific Effects of High Fat Diet on Indices of Metabolic Syndrome in 3xTg-AD Mice: Implications for Alzheimer's Disease. PLoS ONE, 2013, 8, e78554.	2.5	99
361	A Shortened Barnes Maze Protocol Reveals Memory Deficits at 4-Months of Age in the Triple-Transgenic Mouse Model of Alzheimer's Disease. PLoS ONE, 2013, 8, e80355.	2.5	108
362	Modeling Alzheimer's disease: from past to future. Frontiers in Pharmacology, 2013, 4, 77.	3.5	40
363	What Renders TAU Toxic. Frontiers in Neurology, 2013, 4, 72.	2.4	67
364	Imaging of cerebrovascular pathology in animal models of Alzheimer's disease. Frontiers in Aging Neuroscience, 2014, 6, 32.	3.4	71
365	Allopregnanolone and neurogenesis in the nigrostriatal tract. Frontiers in Cellular Neuroscience, 2014, 8, 224.	3.7	16
369	Should development of Alzheimer's disease-specific intravenous immunoglobulin be considered?. Journal of Neuroinflammation, 2014, 11, 198.	7.2	8
370	Models of β -amyloid induced Tau-pathology: the long and β -folded-road to understand the mechanism. Molecular Neurodegeneration, 2014, 9, 51.	10.8	220
371	Increased expression of the receptor for advanced glycation end products in neurons and astrocytes in a triple transgenic mouse model of Alzheimer's disease. Experimental and Molecular Medicine, 2014, 46, e75-e75.	7.7	93
372	Cortical Odor Processing in Health and Disease. Progress in Brain Research, 2014, 208, 275-305.	1.4	58
373	Decrease of ERK/MAPK Overactivation in Prefrontal Cortex Reverses Early Memory Deficit in a Mouse Model of Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 40, 69-82.	2.6	59
374	Blocking the apolipoprotein E/Amyloid β interaction in triple transgenic mice ameliorates Alzheimer's disease related amyloid β and tau pathology. Journal of Neurochemistry, 2014, 128, 577-591.	3.9	50

#	ARTICLE	IF	CITATIONS
375	Down-regulation of serum gonadotropins but not estrogen replacement improves cognition in aged ovariectomized 3xTg-AD female mice. <i>Journal of Neurochemistry</i> , 2014, 130, 115-125.	3.9	44
376	Immunolesion-induced loss of cholinergic projection neurones promotes β -amyloidosis and tau hyperphosphorylation in the hippocampus of triple transgenic mice. <i>Neuropathology and Applied Neurobiology</i> , 2014, 40, 106-120.	3.2	28
377	Animal Models for Brain Research. , 2014, , 3-46.		0
378	Synchrotron-based infrared spectroscopy brings to light the structure of protein aggregates in neurodegenerative diseases. <i>Reviews in Analytical Chemistry</i> , 2014, 33, .	3.2	12
379	Allopregnanolone as regenerative therapeutic for Alzheimer's disease: Translational development and clinical promise. <i>Progress in Neurobiology</i> , 2014, 113, 40-55.	5.7	86
381	Inflammation and Programmed Cell Death in Alzheimer's Disease: Comparison of the Central Nervous System and Peripheral Blood. <i>Molecular Neurobiology</i> , 2014, 50, 463-472.	4.0	16
382	Intracerebroventricular Streptozotocin Exacerbates Alzheimer-Like Changes of 3xTg-AD Mice. <i>Molecular Neurobiology</i> , 2014, 49, 547-562.	4.0	85
383	Tau acts as a mediator for Alzheimer's disease-related synaptic deficits. <i>European Journal of Neuroscience</i> , 2014, 39, 1202-1213.	2.6	43
384	Genetic mouse models of brain ageing and Alzheimer's disease. , 2014, 142, 244-257.		211
385	Down-regulation of Mortalin Exacerbates β -mediated Mitochondrial Fragmentation and Dysfunction. <i>Journal of Biological Chemistry</i> , 2014, 289, 2195-2204.	3.4	58
386	Neurogenesis in neurological and psychiatric diseases and brain injury: From bench to bedside. <i>Progress in Neurobiology</i> , 2014, 115, 116-137.	5.7	69
387	Alzheimer's Disease. , 2014, , 889-920.		1
388	Tritium-labeled (E,E)-2,5-bis(4-hydroxy-3-carboxystyryl)benzene as a probe for β -amyloid fibrils. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 5534-5536.	2.2	4
389	Alzheimer's Disease-Like Pathology Induced by Amyloid- β Oligomers in Nonhuman Primates. <i>Journal of Neuroscience</i> , 2014, 34, 13629-13643.	3.6	189
391	Retinal macroglia changes in a triple transgenic mouse model of Alzheimer's disease. <i>Experimental Eye Research</i> , 2014, 127, 252-260.	2.6	50
392	Autoimmune Manifestations in the 3xTg-AD Model of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2014, 39, 191-210.	2.6	71
393	Impaired Src signaling and post-synaptic actin polymerization in Alzheimer's disease mice hippocampus - Linking NMDA receptors and the reelin pathway. <i>Experimental Neurology</i> , 2014, 261, 698-709.	4.1	27
394	Cardiolipin Profile Changes are Associated to the Early Synaptic Mitochondrial Dysfunction in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2014, 43, 1375-1392.	2.6	90

#	ARTICLE	IF	CITATIONS
395	Early miR-155 upregulation contributes to neuroinflammation in Alzheimer's disease triple transgenic mouse model. <i>Human Molecular Genetics</i> , 2014, 23, 6286-6301.	2.9	133
396	High-fat diet-induced memory impairment in triple-transgenic Alzheimer's disease (3xTgAD) mice is A-independent of changes in amyloid and tau pathology. <i>Neurobiology of Aging</i> , 2014, 35, 1821-1832.	3.1	189
397	Cognitive and emotional profiles of aged Alzheimer's disease (3xTgAD) mice: Effects of environmental enrichment and sexual dimorphism. <i>Behavioural Brain Research</i> , 2014, 268, 185-201.	2.2	61
398	Partial rescue of memory deficits induced by calorie restriction in a mouse model of tau deposition. <i>Behavioural Brain Research</i> , 2014, 271, 79-88.	2.2	59
399	Deficits in odor-guided behaviors in the transgenic 3xTg-AD female mouse model of Alzheimer's disease. <i>Brain Research</i> , 2014, 1572, 18-25.	2.2	18
400	Altered Expression of the CB1 Cannabinoid Receptor in the Triple Transgenic Mouse Model of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2014, 40, 701-712.	2.6	57
401	Pharmacological Modulation of GSAP Reduces Amyloid- β Levels and Tau Phosphorylation in a Mouse Model of Alzheimer's Disease with Plaques and Tangles. <i>Journal of Alzheimer's Disease</i> , 2014, 41, 729-737.	2.6	27
402	Long-term effects of an acute and systemic administration of LPS on adult neurogenesis and spatial memory. <i>Frontiers in Neuroscience</i> , 2014, 8, 83.	2.8	146
403	Human ApoE ϵ 4 Alters Circadian Rhythm Activity, IL-1 β , and GFAP in CRND8 Mice. <i>Journal of Alzheimer's Disease</i> , 2014, 43, 823-834.	2.6	32
404	A critical analysis of the "amyloid cascade hypothesis". <i>Folia Neuropathologica</i> , 2014, 3, 211-225.	1.2	87
405	Age-Dependent Increment of Hydroxymethylation in the Brain Cortex in the Triple-Transgenic Mouse Model of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2014, 41, 845-854.	2.6	41
406	Function and Redox State of Peritoneal Leukocytes as Preclinical and Prodromic Markers in a Longitudinal Study of Triple-Transgenic Mice for Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2014, 43, 213-226.	2.6	21
407	Intracellular oligomeric amyloid-beta rapidly regulates GluA1 subunit of AMPA receptor in the hippocampus. <i>Scientific Reports</i> , 2015, 5, 10934.	3.3	85
408	Alzheimer's Disease Cerebrospinal Fluid and Neuroimaging Biomarkers: Diagnostic Accuracy and Relationship to Drug Efficacy. <i>Journal of Alzheimer's Disease</i> , 2015, 46, 817-836.	2.6	47
409	Identification of Conversion from Normal Elderly Cognition to Alzheimer's Disease using Multimodal Support Vector Machine. <i>Journal of Alzheimer's Disease</i> , 2015, 47, 1057-1067.	2.6	16
410	Age-Dependent Regulation of the Blood-Brain Barrier Influx/Efflux Equilibrium of Amyloid- β Peptide in a Mouse Model of Alzheimer's Disease (3xTg-AD). <i>Journal of Alzheimer's Disease</i> , 2015, 49, 287-300.	2.6	49
411	Yeast Model of Amyloid- β and Tau Aggregation in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 47, 9-16.	2.6	16
412	Differential Effects of Palmitoylethanolamide against Amyloid- β Induced Toxicity in Cortical Neuronal and Astrocytic Primary Cultures from Wild-Type and 3xTg-AD Mice. <i>Journal of Alzheimer's Disease</i> , 2015, 46, 407-421.	2.6	26

#	ARTICLE	IF	CITATIONS
413	Alzheimer's Disease: Mechanism and Approach to Cell Therapy. International Journal of Molecular Sciences, 2015, 16, 26417-26451.	4.1	82
414	Choroid plexus dysfunction impairs beta-amyloid clearance in a triple transgenic mouse model of Alzheimer's disease. Frontiers in Cellular Neuroscience, 2015, 9, 17.	3.7	91
415	Tau Oligomers: The Toxic Player at Synapses in Alzheimer's Disease. Frontiers in Cellular Neuroscience, 2015, 9, 464.	3.7	127
416	Peptides of Presenilin-1 Bind the Amyloid Precursor Protein Ectodomain and Offer a Novel and Specific Therapeutic Approach to Reduce A β -Amyloid in Alzheimer's Disease. PLoS ONE, 2015, 10, e0122451.	2.5	6
417	Nanoscale Synaptic Membrane Mimetic Allows Unbiased High Throughput Screen That Targets Binding Sites for Alzheimer's-Associated A β Oligomers. PLoS ONE, 2015, 10, e0125263.	2.5	28
418	Kynurenine 3-Monooxygenase: An Influential Mediator of Neuropathology. Frontiers in Psychiatry, 2015, 6, 116.	2.6	105
419	Age-Dependent Biochemical Dysfunction in Skeletal Muscle of Triple- Transgenic Mouse Model of Alzheimer's Disease. Current Alzheimer Research, 2015, 12, 100-115.	1.4	22
420	Ceftriaxone ameliorates tau pathology and cognitive decline via restoration of glial glutamate transporter in a mouse model of Alzheimer's disease. Neurobiology of Aging, 2015, 36, 2260-2271.	3.1	128
421	Isolation and characterization of antibody fragments selective for toxic oligomeric tau. Neurobiology of Aging, 2015, 36, 1342-1355.	3.1	25
422	Acyl-coenzyme A:cholesterol acyltransferase 1 blockage enhances autophagy in the neurons of triple transgenic Alzheimer's disease mouse and reduces human P301L-tau content at the presymptomatic stage. Neurobiology of Aging, 2015, 36, 2248-2259.	3.1	67
423	Cognitive and emotional alterations in young Alzheimer's disease (3xTgAD) mice: Effects of neonatal handling stimulation and sexual dimorphism. Behavioural Brain Research, 2015, 281, 156-171.	2.2	42
424	The flavonoid quercetin ameliorates Alzheimer's disease pathology and protects cognitive and emotional function in aged triple transgenic Alzheimer's disease model mice. Neuropharmacology, 2015, 93, 134-145.	4.1	334
425	Neurotoxicity and synaptic plasticity impairment of N-acetylglucosamine polymers: implications for Alzheimer's disease. Neurobiology of Aging, 2015, 36, 1780-1791.	3.1	17
426	Passive immunization targeting the N-terminal projection domain of tau decreases tau pathology and improves cognition in a transgenic mouse model of Alzheimer disease and tauopathies. Journal of Neural Transmission, 2015, 122, 607-617.	2.8	79
427	Depressive-Like Behavior Is Paired to Monoaminergic Alteration in a Murine Model of Alzheimer's Disease. International Journal of Neuropsychopharmacology, 2015, 18, pyu020-pyu020.	2.1	52
428	Neutrophils promote Alzheimer's disease-like pathology and cognitive decline via LFA-1 integrin. Nature Medicine, 2015, 21, 880-886.	30.7	589
429	Hemichannels Are Required for Amyloid A-Peptide-Induced Degranulation and Are Activated in Brain Mast Cells of APP ^{swE} /PS1 ^{dE9} Mice. Journal of Neuroscience, 2015, 35, 9526-9538.	3.6	51
430	Alzheimer's Disease, Drosophila melanogaster and Polyphenols. Advances in Experimental Medicine and Biology, 2015, 863, 21-53.	1.6	6

#	ARTICLE	IF	CITATIONS
431	Utility of Autoantibodies as Biomarkers for Diagnosis and Staging of Neurodegenerative Diseases. International Review of Neurobiology, 2015, 122, 1-51.	2.0	39
432	Propagation of Neuronal Damage to Embryonic Grafts Transplanted in the Hippocampus of Murine Models of Alzheimer's Disease. Rejuvenation Research, 2015, 18, 554-563.	1.8	1
433	Neuronal hyperactivity " A key defect in Alzheimer's disease?. BioEssays, 2015, 37, 624-632.	2.5	182
434	Redox proteomics identification of specifically carbonylated proteins in the hippocampi of triple transgenic Alzheimer's disease mice at its earliest pathological stage. Journal of Proteomics, 2015, 123, 101-113.	2.4	63
435	Growth factor treatment to overcome Alzheimer's dysfunctional signaling. Cellular Signalling, 2015, 27, 1025-1038.	3.6	28
436	Tau Immunotherapy Modulates Both Pathological Tau and Upstream Amyloid Pathology in an Alzheimer's Disease Mouse Model. Journal of Neuroscience, 2015, 35, 4857-4868.	3.6	122
437	Nobiletin, a citrus flavonoid, improves cognitive impairment and reduces soluble A β levels in a triple transgenic mouse model of Alzheimer's disease (3XTg-AD). Behavioural Brain Research, 2015, 289, 69-77.	2.2	111
438	Oxidative stress involving changes in Nrf2 and ER stress in early stages of Alzheimer's disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2015, 1852, 1428-1441.	3.8	137
439	AAV2/1 CD74 Gene Transfer Reduces β -amyloidosis and Improves Learning and Memory in a Mouse Model of Alzheimer's Disease. Molecular Therapy, 2015, 23, 1712-1721.	8.2	34
440	Aberrant Lipid Metabolism in the Forebrain Niche Suppresses Adult Neural Stem Cell Proliferation in an Animal Model of Alzheimer's Disease. Cell Stem Cell, 2015, 17, 397-411.	11.1	192
441	Alterations in synaptic plasticity coincide with deficits in spatial working memory in presymptomatic 3xTg-AD mice. Neurobiology of Learning and Memory, 2015, 125, 152-162.	1.9	67
442	Pharmacologic Inhibition of 5-Lipoxygenase Improves Memory, Rescues Synaptic Dysfunction, and Ameliorates Tau Pathology in a Transgenic Model of Tauopathy. Biological Psychiatry, 2015, 78, 693-701.	1.3	41
443	Aberrant intracellular localization of H3k4me3 demonstrates an early epigenetic phenomenon in Alzheimer's disease. Neurobiology of Aging, 2015, 36, 3121-3129.	3.1	54
444	The Melatonin-Dibenzyl(-methyl)amine Hybrid ITH91/IQM157 Affords Neuroprotection in an in Vitro Alzheimer's Model via Hemo-oxygenase-1 Induction. ACS Chemical Neuroscience, 2015, 6, 288-296.	3.5	27
445	The Role of Cholesterol Metabolism in Alzheimer's Disease. Molecular Neurobiology, 2015, 51, 947-965.	4.0	62
446	Microglial response to Alzheimer's disease is differentially modulated by voluntary wheel running and enriched environments. Brain Structure and Function, 2015, 220, 941-953.	2.3	36
447	Alzheimer's Disease: From Animal Models to the Human Syndrome. , 0, , .		1
448	Mouse Genetic Models of Human Brain Disorders. Frontiers in Genetics, 2016, 7, 40.	2.3	46

#	ARTICLE	IF	CITATIONS
449	Astrocytes As the Main Players in Primary Degenerative Disorders of the Human Central Nervous System. <i>Frontiers in Aging Neuroscience</i> , 2016, 8, 45.	3.4	25
450	Chronic Progressive Neurodegeneration in a Transgenic Mouse Model of Prion Disease. <i>Frontiers in Neuroscience</i> , 2016, 10, 510.	2.8	11
451	Neuronal Gene Targets of NF- κ B and Their Dysregulation in Alzheimer's Disease. <i>Frontiers in Molecular Neuroscience</i> , 2016, 9, 118.	2.9	116
452	Mesenchymal Stem Cells Preserve Working Memory in the 3xTg-AD Mouse Model of Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2016, 17, 152.	4.1	39
453	Redox Proteomic Profiling of Specifically Carbonylated Proteins in the Serum of Triple Transgenic Alzheimer's Disease Mice. <i>International Journal of Molecular Sciences</i> , 2016, 17, 469.	4.1	23
454	Selenomethionine Ameliorates Neuropathology in the Olfactory Bulb of a Triple Transgenic Mouse Model of Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1595.	4.1	12
455	BBB-Permeable, Neuroprotective, and Neurotrophic Polysaccharide, Midi-GAGR. <i>PLoS ONE</i> , 2016, 11, e0149715.	2.5	21
456	Distribution of human umbilical cord blood-derived mesenchymal stem cells in the Alzheimer's disease transgenic mouse after a single intravenous injection. <i>NeuroReport</i> , 2016, 27, 235-241.	1.2	33
457	Therapeutic advantage of pro-electrophilic drugs to activate the Nrf2/ARE pathway in Alzheimer's disease models. <i>Cell Death and Disease</i> , 2016, 7, e2499-e2499.	6.3	71
458	Fibrillar Amyloid- β Accumulation Triggers an Inflammatory Mechanism Leading to Hyperphosphorylation of the Carboxyl-Terminal End of Tau Polypeptide in the Hippocampal Formation of the 3A-Tg-AD Transgenic Mouse. <i>Journal of Alzheimer's Disease</i> , 2016, 52, 243-269.	2.6	19
459	OCT in Central Nervous System Diseases. , 2016, , .		2
460	Animal Models in Neuro Ophthalmology. , 2016, , 239-263.		0
461	Neurochemical Aspects of Alzheimer Disease. , 2016, , 1-76.		1
462	Intramembrane proteolysis within lysosomes. <i>Ageing Research Reviews</i> , 2016, 32, 51-64.	10.9	14
463	Amyloid β -induced astrogliosis is mediated by β 1-integrin via NADPH oxidase 2 in Alzheimer's disease. <i>Ageing Cell</i> , 2016, 15, 1140-1152.	6.7	53
464	Animal Models of Behavior Genetics. , 2016, , .		0
465	Enriched endogenous n-3 polyunsaturated fatty acids alleviate cognitive and behavioral deficits in a mice model of Alzheimer's disease. <i>Neuroscience</i> , 2016, 333, 345-355.	2.3	22
466	Alzheimer's Disease Cerebrospinal Fluid (CSF) Biomarkers. , 2016, , 139-180.		4

#	ARTICLE	IF	CITATIONS
467	Neurodegenerative Diseases and Dementia. , 2016, , 167-197.		0
468	Abolished perineuronal nets and altered parvalbumin-immunoreactivity in the nucleus reticularis thalami of wildtype and 3xTg mice after experimental stroke. Neuroscience, 2016, 337, 66-87.	2.3	9
469	With mouse age comes wisdom: A review and suggestions of relevant mouse models for age-related conditions. Mechanisms of Ageing and Development, 2016, 160, 54-68.	4.6	14
470	Selenomethionine reduces the deposition of beta-amyloid plaques by modulating β -secretase and enhancing selenoenzymatic activity in a mouse model of Alzheimer's disease. Metallomics, 2016, 8, 782-789.	2.4	28
471	Aberrant expression of the pore-forming KATP channel subunit Kir6.2 in hippocampal reactive astrocytes in the 3xTg-AD mouse model and human Alzheimer's disease. Neuroscience, 2016, 336, 81-101.	2.3	26
472	Novel insights into multitargeted potential of N ^ε -(4-benzylpiperidin-1-yl)alkylamine derivatives in the management of Alzheimer's disease associated pathogenesis. RSC Advances, 2016, 6, 104847-104867.	3.6	7
473	Neuroprotective effects of bee venom phospholipase A2 in the 3xTg AD mouse model of Alzheimer's disease. Journal of Neuroinflammation, 2016, 13, 10.	7.2	61
474	Astrocytes in physiological aging and Alzheimer's disease. Neuroscience, 2016, 323, 170-182.	2.3	331
475	Memory and learning seems to be related to cholinergic dysfunction in the JE rat model. Physiology and Behavior, 2016, 156, 148-155.	2.1	14
476	Validation and Characterization of a Novel Peptide That Binds Monomeric and Aggregated β -Amyloid and Inhibits the Formation of Neurotoxic Oligomers. Journal of Biological Chemistry, 2016, 291, 547-559.	3.4	15
477	Molecular Pathways in Alzheimer's Disease and Cognitive Function. , 2016, , 135-167.		1
478	Peripherally administered sera antibodies recognizing amyloid- β oligomers mitigate Alzheimer's disease-like pathology and cognitive decline in aged 3xTg-AD mice. Vaccine, 2016, 34, 1758-1766.	3.8	11
479	Therapeutic Potentials of Curcumin for Alzheimer Disease. , 2016, , .		13
480	Reduced apurinic/apyrimidinic endonuclease 1 activity and increased DNA damage in mitochondria are related to enhanced apoptosis and inflammation in the brain of senescence- accelerated P8 mice (SAMP8). Biogerontology, 2016, 17, 325-335.	3.9	9
481	Early alterations in blood and brain RANTES and MCP-1 expression and the effect of exercise frequency in the 3xTg-AD mouse model of Alzheimer's disease. Neuroscience Letters, 2016, 610, 165-170.	2.1	24
482	Novel biphenyl bis -sulfonamides as acetyl and butyrylcholinesterase inhibitors: Synthesis, biological evaluation and molecular modeling studies. Bioorganic Chemistry, 2016, 64, 13-20.	4.1	56
483	Neuroregeneration: Disease Modeling and Therapeutic Strategies for Alzheimer's and Parkinson's Diseases. Biosystems and Biorobotics, 2016, , 293-325.	0.3	2
486	Selenomethionine Mitigates Cognitive Decline by Targeting Both Tau Hyperphosphorylation and Autophagic Clearance in an Alzheimer's Disease Mouse Model. Journal of Neuroscience, 2017, 37, 2449-2462.	3.6	106

#	ARTICLE	IF	CITATIONS
487	Tetracyclic Truncated Analogue of the Marine Toxin Gambierol Modifies NMDA, Tau, and Amyloid β^2 Expression in Mice Brains: Implications in AD Pathology. ACS Chemical Neuroscience, 2017, 8, 1358-1367.	3.5	15
488	An Efficient Synthesis of <i>2</i> -Aryl Pyrimidine Heterocycles: Potential New Drug Candidates to Treat Alzheimer's Disease. Archiv Der Pharmazie, 2017, 350, 1600304.	4.1	22
489	Berberine improves cognitive impairment by promoting autophagic clearance and inhibiting production of β^2 -amyloid in APP/tau/PS1 mouse model of Alzheimer's disease. Experimental Gerontology, 2017, 91, 25-33.	2.8	122
490	Disease-Modifying Effects of M ₁ Muscarinic Acetylcholine Receptor Activation in an Alzheimer's Disease Mouse Model. ACS Chemical Neuroscience, 2017, 8, 1177-1187.	3.5	36
491	Involvement of GluN2B subunit containing N-methyl- d -aspartate (NMDA) receptors in mediating the acute and chronic synaptotoxic effects of oligomeric amyloid-beta ($A\beta^2$) in murine models of Alzheimer's disease (AD). Neuropharmacology, 2017, 123, 100-115.	4.1	29
492	Prevention of Amyloid- β^2 and Tau Pathologies, Associated Neurodegeneration, and Cognitive Deficit by Early Treatment with a Neurotrophic Compound. Journal of Alzheimer's Disease, 2017, 58, 215-230.	2.6	18
493	Preclinical models of Alzheimer's disease for identification and preclinical validation of therapeutic targets: from fine-tuning strategies for validated targets to new venues for therapy. , 2017, , 115-156.		2
494	The contribution of transgenic and nontransgenic animal models in Alzheimer's disease drug research and development. Behavioural Pharmacology, 2017, 28, 95-111.	1.7	8
495	Developmental toxicant exposure in a mouse model of Alzheimer's disease induces differential sex-associated microglial activation and increased susceptibility to amyloid accumulation. Journal of Developmental Origins of Health and Disease, 2017, 8, 493-501.	1.4	7
496	Protein Phosphorylation is a Key Mechanism in Alzheimer's Disease. Journal of Alzheimer's Disease, 2017, 58, 953-978.	2.6	57
497	In Vivo Detection of Gray Matter Neuropathology in the 3xTg Mouse Model of Alzheimer's Disease with Diffusion Tensor Imaging. Journal of Alzheimer's Disease, 2017, 58, 841-853.	2.6	21
498	A critical overview of therapeutic strategy and advancement for Alzheimer's disease treatment. Journal of the Taiwan Institute of Chemical Engineers, 2017, 77, 92-105.	5.3	11
499	Cotinine improves visual recognition memory and decreases cortical Tau phosphorylation in the Tg6799 mice. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2017, 78, 75-81.	4.8	28
500	Cathepsin B Improves β^2 -Amyloidosis and Learning and Memory in Models of Alzheimer's Disease. Journal of Neuroimmune Pharmacology, 2017, 12, 340-352.	4.1	51
501	Novel 2-Arylbenzimidazole derivatives as multi-targeting agents to treat Alzheimer's disease. Medicinal Chemistry Research, 2017, 26, 1506-1515.	2.4	9
502	Nanotechnological strategies for nerve growth factor delivery: Therapeutic implications in Alzheimer's disease. Pharmacological Research, 2017, 120, 68-87.	7.1	67
503	Membrane association and release of wild-type and pathological tau from organotypic brain slice cultures. Cell Death and Disease, 2017, 8, e2671-e2671.	6.3	50
504	Amyloid-Beta and Phosphorylated Tau Accumulations Cause Abnormalities at Synapses of Alzheimer's disease Neurons. Journal of Alzheimer's Disease, 2017, 57, 975-999.	2.6	294

#	ARTICLE	IF	CITATIONS
505	Alzheimer's disease: experimental models and reality. <i>Acta Neuropathologica</i> , 2017, 133, 155-175.	7.7	513
506	Altered Gut Microbiome Composition and Tryptic Activity of the 5xFAD Alzheimer's Mouse Model. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 775-788.	2.6	230
507	Impairments in spatial representations and rhythmic coordination of place cells in the 3xTg mouse model of Alzheimer's disease. <i>Hippocampus</i> , 2017, 27, 378-392.	1.9	85
509	An inhibitor of the proteasomal deubiquitinating enzyme USP14 induces tau elimination in cultured neurons. <i>Journal of Biological Chemistry</i> , 2017, 292, 19209-19225.	3.4	98
510	Design and Application of Anti-Amyloid Peptide-Based Inhibitors as a Therapeutic Strategy of Alzheimer's Disease. <i>World Scientific Lecture and Course Notes in Chemistry</i> , 2017, , 73-111.	0.2	1
511	Lessons from Anti-Amyloid- β Immunotherapies in Alzheimer Disease: Aiming at a Moving Target. <i>Neurodegenerative Diseases</i> , 2017, 17, 242-250.	1.4	34
512	Inhibition of glycogen synthase kinase-3 by BTA-EG4 reduces tau abnormalities in an organotypic brain slice culture model of Alzheimer's disease. <i>Scientific Reports</i> , 2017, 7, 7434.	3.3	20
513	Cognitive Decline in Preclinical Alzheimer's Disease: Amyloid-Beta versus Tauopathy. <i>Journal of Alzheimer's Disease</i> , 2017, 61, 265-281.	2.6	99
514	Normalizing the gene dosage of Dyrk1A in a mouse model of Down syndrome rescues several Alzheimer's disease phenotypes. <i>Neurobiology of Disease</i> , 2017, 106, 76-88.	4.4	72
515	Hippocampal 5-HT1A receptor expression changes in prodromal stages of Alzheimer's disease: Beneficial or deleterious?. <i>Neuropharmacology</i> , 2017, 123, 446-454.	4.1	22
516	Central insulin dysregulation and energy dyshomeostasis in two mouse models of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2017, 58, 1-13.	3.1	71
517	Alzheimer's Disease: Insights from Genetic Mouse Models and Current Advances in Human iPSC-Derived Neurons. <i>Advances in Neurobiology</i> , 2017, 15, 3-29.	1.8	4
518	The transcription factor XBP1s restores hippocampal synaptic plasticity and memory by control of the Kalirin-7 pathway in Alzheimer model. <i>Molecular Psychiatry</i> , 2017, 22, 1562-1575.	7.9	79
519	Neurovascular Specifications in the Alzheimer-Like Brain of Mice Affected by Focal Cerebral Ischemia: Implications for Future Therapies. <i>Journal of Alzheimer's Disease</i> , 2017, 59, 655-674.	2.6	8
520	An Intracellular Amyloid- β /A β PP Epitope Correlates with Neurodegeneration in those Neuronal Populations Early Involved in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 59, 1079-1096.	2.6	15
521	Animal Models of Alzheimer's Disease. , 2017, , 31-58.		1
522	Early-Onset Network Hyperexcitability in Presymptomatic Alzheimer's Disease Transgenic Mice Is Suppressed by Passive Immunization with Anti-Human APP/A β Antibody and by mGluR5 Blockade. <i>Frontiers in Aging Neuroscience</i> , 2017, 9, 71.	3.4	75
523	Increased Calcium-Sensing Receptor Immunoreactivity in the Hippocampus of a Triple Transgenic Mouse Model of Alzheimer's Disease. <i>Frontiers in Neuroscience</i> , 2017, 11, 81.	2.8	16

#	ARTICLE	IF	CITATIONS
524	Age-dependent regulation of obesity and Alzheimer-related outcomes by hormone therapy in female 3xTg-AD mice. PLoS ONE, 2017, 12, e0178490.	2.5	26
525	Tau accumulation in the retina promotes early neuronal dysfunction and precedes brain pathology in a mouse model of Alzheimer's disease. Molecular Neurodegeneration, 2017, 12, 58.	10.8	99
526	Transgenic autoinhibition of p21-activated kinase exacerbates synaptic impairments and fronto-dependent behavioral deficits in an animal model of Alzheimer's disease. Aging, 2017, 9, 1386-1403.	3.1	16
527	Carboxy-Terminus Tau Protein Hyperphosphorylation is Associated with Extracellular Deposits of Amyloid- β Fibrillary in a Triple-Transgenic Model of Alzheimer's Disease. Journal of Neurological Disorders, 2017, 05, .	0.1	0
528	Prospects for strain-specific immunotherapy in Alzheimer's disease and tauopathies. Npj Vaccines, 2018, 3, 9.	6.0	45
529	Pathogenic Mechanisms of Heavy Metal Induced-Alzheimer's Disease. Toxicology and Environmental Health Sciences, 2018, 10, 1-10.	2.1	45
530	Synaptotoxic Signaling by Amyloid Beta Oligomers in Alzheimer's Disease Through Prion Protein and mGluR5. Advances in Pharmacology, 2018, 82, 293-323.	2.0	67
531	Chronic Lithium Treatment Increases Telomere Length in Parietal Cortex and Hippocampus of Triple-Transgenic Alzheimer's Disease Mice. Journal of Alzheimer's Disease, 2018, 63, 93-101.	2.6	20
532	Phosphorylation of Tau protein correlates with changes in hippocampal theta oscillations and reduces hippocampal excitability in Alzheimer's model. Journal of Biological Chemistry, 2018, 293, 8462-8472.	3.4	59
533	Beneficial effects of white wine polyphenols-enriched diet on Alzheimer's disease-like pathology. Journal of Nutritional Biochemistry, 2018, 55, 165-177.	4.2	36
534	Profiles of β -Amyloid Peptides and Key Secretases in Brain Autopsy Samples Differ with Sex and APOE ϵ 4 Status: Impact for Risk and Progression of Alzheimer Disease. Neuroscience, 2018, 373, 20-36.	2.3	45
535	Mutations in the β -amyloid precursor protein in familial Alzheimer's disease increase β oligomer production in cellular models. Heliyon, 2018, 4, e00511.	3.2	10
536	Mouse models of neurodegenerative disease: preclinical imaging and neurovascular component. Brain Imaging and Behavior, 2018, 12, 1160-1196.	2.1	8
537	Disrupted Neuroglial Metabolic Coupling after Peripheral Surgery. Journal of Neuroscience, 2018, 38, 452-464.	3.6	44
538	Chronic deep brain stimulation in an Alzheimer's disease mouse model enhances memory and reduces pathological hallmarks. Brain Stimulation, 2018, 11, 435-444.	1.6	49
539	Preparation of organotypic brain slice cultures for the study of Alzheimer's disease. F1000Research, 2018, 7, 592.	1.6	14
540	Active full-length DNA β 42 immunization in 3xTg-AD mice reduces not only amyloid deposition but also tau pathology. Alzheimer's Research and Therapy, 2018, 10, 115.	6.2	36
541	Inhibition of HDAC3 reverses Alzheimer's disease-related pathologies in vitro and in the 3xTg-AD mouse model. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E11148-E11157.	7.1	140

#	ARTICLE	IF	CITATIONS
542	Phytochemicals from <i>Achillea fragrantissima</i> are Modulators of A β PP Metabolism. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 1425-1435.	2.6	5
543	Spatiotemporal activation of the C/EBP β /IL-1 β -secretase axis regulates the pathogenesis of Alzheimer's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E12427-E12434.	7.1	21
544	Can Arginase Inhibitors Be the Answer to Therapeutic Challenges in Alzheimer's Disease?. <i>Neurotherapeutics</i> , 2018, 15, 1032-1035.	4.4	8
545	Mini-GAGR, an intranasally applied polysaccharide, activates the neuronal Nrf2-mediated antioxidant defense system. <i>Journal of Biological Chemistry</i> , 2018, 293, 18242-18269.	3.4	27
546	Bis(9)-(4'-Meptazinol, a novel dual-binding AChE inhibitor, rescues cognitive deficits and pathological changes in APP/PS1 transgenic mice. <i>Translational Neurodegeneration</i> , 2018, 7, 21.	8.0	14
547	Microglia in neurodegeneration. <i>Nature Neuroscience</i> , 2018, 21, 1359-1369.	14.8	1,034
548	Pharmacokinetics in Rat of P8, a Peptide Drug Candidate for the Treatment of Alzheimer's Disease: Stability and Delivery to the Brain. <i>Journal of Alzheimer's Disease Reports</i> , 2018, 2, 169-179.	2.2	5
549	The Biology of Glial Cells and Their Complex Roles in Alzheimer's Disease: New Opportunities in Therapy. <i>Biomolecules</i> , 2018, 8, 93.	4.0	38
550	Novel Key Players in the Development of Tau Neuropathology: Focus on the 5-Lipoxygenase. <i>Journal of Alzheimer's Disease</i> , 2018, 64, S481-S489.	2.6	7
551	Loss of calretinin and parvalbumin positive interneurons in the hippocampal CA1 of aged Alzheimer's disease mice. <i>Neuroscience Letters</i> , 2018, 681, 19-25.	2.1	40
552	Improved synaptic and cognitive function in aged 3xTg-AD mice with reduced amyloid- β after immunotherapy with a novel recombinant 6A β 15-TF chimeric vaccine. <i>Clinical Immunology</i> , 2018, 193, 12-23.	3.2	4
553	Palmitoylethanolamide Dampens Reactive Astrogliosis and Improves Neuronal Trophic Support in a Triple Transgenic Model of Alzheimer's Disease: <i>In Vitro</i> and <i>In Vivo</i> Evidence. <i>Oxidative Medicine and Cellular Longevity</i> , 2018, 2018, 1-14.	4.0	48
554	Selenium-enriched yeast inhibited β -amyloid production and modulated autophagy in a triple transgenic mouse model of Alzheimer's disease. <i>Metallomics</i> , 2018, 10, 1107-1115.	2.4	26
555	Oxidation of KCNB1 channels in the human brain and in mouse model of Alzheimer's disease. <i>Cell Death and Disease</i> , 2018, 9, 820.	6.3	20
556	Intraneuronal accumulation of C99 contributes to synaptic alterations, apathy-like behavior, and spatial learning deficits in 3xTg-AD and 2xTg-AD mice. <i>Neurobiology of Aging</i> , 2018, 71, 21-31.	3.1	40
557	Using Molecular Tweezers to Remodel Abnormal Protein Self-Assembly and Inhibit the Toxicity of Amyloidogenic Proteins. <i>Methods in Molecular Biology</i> , 2018, 1777, 369-386.	0.9	12
558	The Role of Fluoxetine in Activating Wnt/ β -Catenin Signaling and Repressing β -Amyloid Production in an Alzheimer Mouse Model. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 164.	3.4	34
559	Specific deletion connexin43 in astrocyte ameliorates cognitive dysfunction in APP/PS1 mice. <i>Life Sciences</i> , 2018, 208, 175-191.	4.3	44

#	ARTICLE	IF	CITATIONS
560	Hyaluronic acid is present on specific perineuronal nets in the mouse cerebral cortex. Brain Research, 2018, 1698, 139-150.	2.2	5
561	The Amyloid- β^2 Oligomer Hypothesis: Beginning of the Third Decade. Journal of Alzheimer's Disease, 2018, 64, S567-S610.	2.6	572
562	Biliverdin Reductase-A Mediates the Beneficial Effects of Intranasal Insulin in Alzheimer Disease. Molecular Neurobiology, 2019, 56, 2922-2943.	4.0	70
563	Arsenic Exposure Contributes to the Bioenergetic Damage in an Alzheimer's Disease Model. ACS Chemical Neuroscience, 2019, 10, 323-336.	3.5	39
564	IL-6 trans-signaling in the brain influences the behavioral and physio-pathological phenotype of the Tg2576 and 3xTgAD mouse models of Alzheimer's disease. Brain, Behavior, and Immunity, 2019, 82, 145-159.	4.1	26
565	Reversibility of Age-related Oxidized Free NADH Redox States in Alzheimer's Disease Neurons by Imposed External Cys/CySS Redox Shifts. Scientific Reports, 2019, 9, 11274.	3.3	20
566	Potential Benefits of Nobiletin, A Citrus Flavonoid, against Alzheimer's Disease and Parkinson's Disease. International Journal of Molecular Sciences, 2019, 20, 3380.	4.1	126
567	Animal models of olfactory dysfunction in neurodegenerative diseases. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2019, 164, 431-452.	1.8	12
568	Impact of Chronic Risperidone Use on Behavior and Survival of 3xTg-AD Mice Model of Alzheimer's Disease and Mice With Normal Aging. Frontiers in Pharmacology, 2019, 10, 1061.	3.5	16
569	Bexarotene therapy ameliorates behavioral deficits and induces functional and molecular changes in very-old Triple Transgenic Mice model of Alzheimer's disease. PLoS ONE, 2019, 14, e0223578.	2.5	22
570	Flavanol-rich lychee fruit extract substantially reduces progressive cognitive and molecular deficits in a triple-transgenic animal model of Alzheimer disease. Nutritional Neuroscience, 2019, 24, 1-15.	3.1	5
571	Effects of the Novel IDO Inhibitor DWG-1036 on the Behavior of Male and Female 3xTg-AD Mice. Frontiers in Pharmacology, 2019, 10, 1044.	3.5	33
572	Treatment with scFv-h3D6 Prevented Neuronal Loss and Improved Spatial Memory in Young 3xTg-AD Mice by Reducing the Intracellular Amyloid- β^2 Burden. Journal of Alzheimer's Disease, 2019, 70, 1069-1091.	2.6	18
573	Amyloid β^2 -Induced Upregulation of Nav1.6 Underlies Neuronal Hyperactivity in Tg2576 Alzheimer's Disease Mouse Model. Scientific Reports, 2019, 9, 13592.	3.3	49
574	Neuroglia in Neurodegenerative Diseases. Advances in Experimental Medicine and Biology, 2019, , .	1.6	18
575	Tau and mTOR: The Hotspots for Multifarious Diseases in Alzheimer's Development. Frontiers in Neuroscience, 2018, 12, 1017.	2.8	65
576	Pharmacokinetic parameters and mechanism of action of an efficient anti- $A\beta^2$ single chain antibody fragment. PLoS ONE, 2019, 14, e0217793.	2.5	9
577	Can Healthy Diets, Regular Exercise, and Better Lifestyle Delay the Progression of Dementia in Elderly Individuals?. Journal of Alzheimer's Disease, 2019, 72, S37-S58.	2.6	36

#	ARTICLE	IF	CITATIONS
578	Preventive Effect of Quercetin in a Triple Transgenic Alzheimer's Disease Mice Model. <i>Molecules</i> , 2019, 24, 2287.	3.8	63
579	Transcriptomic Insights into the Response of the Olfactory Bulb to Selenium Treatment in a Mouse Model of Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2998.	4.1	14
580	Astrocyte Function Is Affected by Aging and Not Alzheimer's Disease: A Preliminary Investigation in Hippocampi of 3xTg-AD Mice. <i>Frontiers in Pharmacology</i> , 2019, 10, 644.	3.5	32
581	Chronic Dyrk1 Inhibition Delays the Onset of AD-Like Pathology in 3xTg-AD Mice. <i>Molecular Neurobiology</i> , 2019, 56, 8364-8375.	4.0	25
582	The role of APOE in transgenic mouse models of AD. <i>Neuroscience Letters</i> , 2019, 707, 134285.	2.1	37
583	Mitochondrial Movement and Number Deficits in Embryonic Cortical Neurons from 3xTg-AD Mice. <i>Journal of Alzheimer's Disease</i> , 2019, 70, 139-151.	2.6	6
584	Age and sex differences in motivation and spatial working memory in 3xTg-AD mice in the Hebb-Williams maze. <i>Behavioural Brain Research</i> , 2019, 370, 111937.	2.2	16
585	A multifunctional therapeutic approach: Synthesis, biological evaluation, crystal structure and molecular docking of diversified 1H-pyrazolo[3,4-b]pyridine derivatives against Alzheimer's disease. <i>European Journal of Medicinal Chemistry</i> , 2019, 175, 2-19.	5.5	53
586	Transcranial direct current stimulation does not improve memory deficits or alter pathological hallmarks in a rodent model of Alzheimer's disease. <i>Journal of Psychiatric Research</i> , 2019, 114, 93-98.	3.1	14
587	Regional hypometabolism in the 3xTg mouse model of Alzheimer's disease. <i>Neurobiology of Disease</i> , 2019, 127, 264-277.	4.4	36
588	Temporal and regional progression of Alzheimer's disease-like pathology in 3xTg-AD mice. <i>Aging Cell</i> , 2019, 18, e12873.	6.7	171
589	Altered slow (<1 Hz) and fast (beta and gamma) neocortical oscillations in the 3xTg-AD mouse model of Alzheimer's disease under anesthesia. <i>Neurobiology of Aging</i> , 2019, 79, 142-151.	3.1	23
590	Impaired Glucose Tolerance and Reduced Plasma Insulin Precede Decreased AKT Phosphorylation and GLUT3 Translocation in the Hippocampus of Old 3xTg-AD Mice. <i>Journal of Alzheimer's Disease</i> , 2019, 68, 809-837.	2.6	30
591	Alcohol drinking exacerbates neural and behavioral pathology in the 3xTg-AD mouse model of Alzheimer's disease. <i>International Review of Neurobiology</i> , 2019, 148, 169-230.	2.0	56
592	Retinal thinning of inner sub-layers is associated with cortical atrophy in a mouse model of Alzheimer's disease: a longitudinal multimodal in vivo study. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 90.	6.2	32
593	Selective memory and behavioral alterations after ambient ultrafine particulate matter exposure in aged 3xTgAD Alzheimer's disease mice. <i>Particle and Fibre Toxicology</i> , 2019, 16, 45.	6.2	32
594	Organotypic brain slice cultures to model neurodegenerative proteinopathies. <i>Molecular Neurodegeneration</i> , 2019, 14, 45.	10.8	69
595	Redox proteomics and amyloid β -peptide: insights into Alzheimer disease. <i>Journal of Neurochemistry</i> , 2019, 151, 459-487.	3.9	80

#	ARTICLE	IF	CITATIONS
596	Motor deficits in 16-month-old male and female 3xTg-AD mice. Behavioural Brain Research, 2019, 356, 305-313.	2.2	32
597	Contributions of a high-fat diet to Alzheimer's disease-related decline: A longitudinal behavioural and structural neuroimaging study in mouse models. NeuroImage: Clinical, 2019, 21, 101606.	2.7	59
598	Peripheral adaptive immunity of the triple transgenic mouse model of Alzheimer's disease. Journal of Neuroinflammation, 2019, 16, 3.	7.2	36
599	Dissociable cognitive impairments in two strains of transgenic Alzheimer's disease mice revealed by a battery of object-based tests. Scientific Reports, 2019, 9, 57.	3.3	45
600	Obstacles to translating the promise of nanoparticles into viable amyloid disease therapeutics. Physical Biology, 2019, 16, 021002.	1.8	2
601	Diffusion MRI detects longitudinal white matter changes in the 3xTg-AD mouse model of Alzheimer's disease. Magnetic Resonance Imaging, 2019, 57, 235-242.	1.8	14
602	Hippocampal Proteomic Alteration in Triple Transgenic Mouse Model of Alzheimer's Disease and Implication of PINK 1 Regulation in Donepezil Treatment. Journal of Proteome Research, 2019, 18, 1542-1552.	3.7	31
603	Sex differences in the timing behavior performance of 3xTg-AD and wild-type mice in the peak interval procedure. Behavioural Brain Research, 2019, 360, 235-243.	2.2	21
604	TSPO and amyloid deposits in sub-regions of the hippocampus in the 3xTgAD mouse model of Alzheimer's disease. Neurobiology of Disease, 2019, 121, 95-105.	4.4	42
605	Can Animal Models Inform on the Relationship between Depression and Alzheimer Disease?. Canadian Journal of Psychiatry, 2019, 64, 18-29.	1.9	9
606	Mechanisms of secretion and spreading of pathological tau protein. Cellular and Molecular Life Sciences, 2020, 77, 1721-1744.	5.4	174
607	Berberine mitigates cognitive decline in an Alzheimer's Disease Mouse Model by targeting both tau hyperphosphorylation and autophagic clearance. Biomedicine and Pharmacotherapy, 2020, 121, 109670.	5.6	78
608	Sowing the Seeds of Discovery: Tau-Propagation Models of Alzheimer's Disease. ACS Chemical Neuroscience, 2020, 11, 3499-3509.	3.5	7
609	Ultrasound with microbubbles improves memory, ameliorates pathology and modulates hippocampal proteomic changes in a triple transgenic mouse model of Alzheimer's disease. Theranostics, 2020, 10, 11794-11819.	10.0	55
610	Chronic Airway Allergy Induces Pro-Inflammatory Responses in the Brain of Wildtype Mice but Not 3xTgAD Mice. Neuroscience, 2020, 448, 14-27.	2.3	0
611	Cognitive Impairment in the 3xTg-AD Mouse Model of Alzheimer's Disease is Affected by A β 2-ImmunoTherapy and Cognitive Stimulation. Pharmaceutics, 2020, 12, 944.	4.5	17
612	Sex-dependent alterations in the physiology of entorhinal cortex neurons in old heterozygous 3xTg-AD mice. Biology of Sex Differences, 2020, 11, 63.	4.1	12
613	Epigenetic basis of Alzheimer disease. World Journal of Biological Chemistry, 2020, 11, 62-75.	4.3	20

#	ARTICLE	IF	CITATIONS
614	Sex-Specific Effects of Chronic Creatine Supplementation on Hippocampal-Mediated Spatial Cognition in the 3xTg Mouse Model of Alzheimer's Disease. <i>Nutrients</i> , 2020, 12, 3589.	4.1	12
615	Characterization and Discovery of a Selective Small-Molecule Modulator of Mitochondrial Complex I Targeting a Unique Binding Site. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 11819-11830.	6.4	5
616	Prenatal to early postnatal neurotrophic treatment prevents Alzheimer-like behavior and pathology in mice. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 102.	6.2	7
617	Transcriptional, Behavioral and Biochemical Profiling in the 3xTg-AD Mouse Model Reveals a Specific Signature of Amyloid Deposition and Functional Decline in Alzheimer's Disease. <i>Frontiers in Neuroscience</i> , 2020, 14, 602642.	2.8	3
618	Model organism development and evaluation for late-onset Alzheimer's disease: MODEL-AD. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020, 6, e12110.	3.7	63
619	High Mobility Group Box 1 Ameliorates Cognitive Impairment in the 3xTg-AD Mouse Model. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 851-864.	2.6	5
620	Dysregulated expression of monoacylglycerol lipase is a marker for anti-diabetic drug metformin-targeted therapy to correct impaired neurogenesis and spatial memory in Alzheimer's disease. <i>Theranostics</i> , 2020, 10, 6337-6360.	10.0	22
621	Characterization of the retinal changes of the 3xTg-AD mouse model of Alzheimer's disease. <i>Health and Technology</i> , 2020, 10, 875-883.	3.6	4
622	Scattering Angle Resolved Optical Coherence Tomography Detects Early Changes in 3xTg Alzheimer's Disease Mouse Model. <i>Translational Vision Science and Technology</i> , 2020, 9, 18.	2.2	10
623	Young blood plasma reduces Alzheimer's disease-like brain pathologies and ameliorates cognitive impairment in 3xTg-AD mice. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 70.	6.2	27
624	Early Onset of Sex-Dependent Mitochondrial Deficits in the Cortex of 3xTg Alzheimer's Mice. <i>Cells</i> , 2020, 9, 1541.	4.1	20
625	Allopregnanolone Promotes Neuronal and Oligodendrocyte Differentiation In Vitro and In Vivo: Therapeutic Implication for Alzheimer's Disease. <i>Neurotherapeutics</i> , 2020, 17, 1813-1824.	4.4	15
626	IL-6 Trans-Signaling in the Brain Influences the Metabolic Phenotype of the 3xTg-AD Mouse Model of Alzheimer's Disease. <i>Cells</i> , 2020, 9, 1605.	4.1	11
627	Intermittent fasting promotes adult hippocampal neuronal differentiation by activating GSK-3 β in 3xTg-AD mice. <i>Journal of Neurochemistry</i> , 2020, 155, 697-713.	3.9	20
628	Diffusion MRI detects early brain microstructure abnormalities in 3-month-old 3xTg-AD mice. <i>NMR in Biomedicine</i> , 2020, 33, e4346.	2.8	11
629	Astrocytic palmitoylethanolamide pre-exposure exerts neuroprotective effects in astrocyte-neuron co-cultures from a triple transgenic mouse model of Alzheimer's disease. <i>Life Sciences</i> , 2020, 257, 118037.	4.3	14
630	Chronic Oral Palmitoylethanolamide Administration Rescues Cognitive Deficit and Reduces Neuroinflammation, Oxidative Stress, and Glutamate Levels in A Transgenic Murine Model of Alzheimer's Disease. <i>Journal of Clinical Medicine</i> , 2020, 9, 428.	2.4	26
631	Progression of Alzheimer's disease and effect of scFv α 3D6 immunotherapy in the 3xTg-AD mouse model: An in vivo longitudinal study using Magnetic Resonance Imaging and Spectroscopy. <i>NMR in Biomedicine</i> , 2020, 33, e4263.	2.8	13

#	ARTICLE	IF	CITATIONS
632	Impairment of PGC-1 α -mediated mitochondrial biogenesis precedes mitochondrial dysfunction and Alzheimer's pathology in the 3xTg mouse model of Alzheimer's disease. <i>Experimental Gerontology</i> , 2020, 133, 110882.	2.8	34
633	Alzheimer's disease pathology in APOE transgenic mouse models: The Who, What, When, Where, Why, and How. <i>Neurobiology of Disease</i> , 2020, 139, 104811.	4.4	44
634	Inhibition of 5 α -Reductase Impairs Cognitive Performance, Alters Dendritic Morphology and Increases Tau Phosphorylation in the Hippocampus of Male 3xTg-AD Mice. <i>Neuroscience</i> , 2020, 429, 185-202.	2.3	14
635	Hippocampal Deficits in Amyloid- β -Related Rodent Models of Alzheimer's Disease. <i>Frontiers in Neuroscience</i> , 2020, 14, 266.	2.8	44
636	An agent-based model to investigate microbial initiation of Alzheimer's disease via the olfactory system. <i>Theoretical Biology and Medical Modelling</i> , 2020, 17, 5.	2.1	7
637	Spatial reference learning deficits in absence of dysfunctional working memory in the TgF344-AD rat model of Alzheimer's disease. <i>Genes, Brain and Behavior</i> , 2021, 20, e12712.	2.2	14
638	Targeted metabolomics study of early pathological features in hippocampus of triple transgenic Alzheimer's disease male mice. <i>Journal of Neuroscience Research</i> , 2021, 99, 927-946.	2.9	17
639	Selective linkage of mitochondrial enzymes to intracellular calcium stores differs between human-induced pluripotent stem cells, neural stem cells, and neurons. <i>Journal of Neurochemistry</i> , 2021, 156, 867-879.	3.9	2
640	Molecular Mechanisms of Metal Toxicity in the Pathogenesis of Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2021, 58, 1-20.	4.0	72
641	Does hearing loss lead to dementia? A review of the literature. <i>Hearing Research</i> , 2021, 402, 108038.	2.0	37
642	Melatonin ameliorates microvessel abnormalities in the cerebral cortex and hippocampus in a rat model of Alzheimer's disease. <i>Neural Regeneration Research</i> , 2021, 16, 757.	3.0	14
643	The A β (1-38) peptide is a negative regulator of the A β (1-42) peptide implicated in Alzheimer disease progression. <i>Scientific Reports</i> , 2021, 11, 431.	3.3	32
644	Spatial memory deficiency early in 6xTg Alzheimer's disease mouse model. <i>Scientific Reports</i> , 2021, 11, 1334.	3.3	24
645	Proteomic Profiling of Cerebrum Mitochondria, Myelin Sheath, and Synaptosome Revealed Mitochondrial Damage and Synaptic Impairments in Association with 3 \times Tg-AD Mice Model. <i>Cellular and Molecular Neurobiology</i> , 2022, 42, 1745-1763.		9
646	Extracellular Vesicles From 3xTg-AD Mouse and Alzheimer's Disease Patient Astrocytes Impair Neuroglial and Vascular Components. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 593927.	3.4	24
647	Heterotypic interactions in amyloid function and disease. <i>FEBS Journal</i> , 2022, 289, 2025-2046.	4.7	18
648	Tetramethylpyrazine Improves Cognitive Impairment and Modifies the Hippocampal Proteome in Two Mouse Models of Alzheimer's Disease. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 632843.	3.7	17
649	Neuronal Network Excitability in Alzheimer's Disease: The Puzzle of Similar versus Divergent Roles of Amyloid β and Tau. <i>ENeuro</i> , 2021, 8, ENEURO.0418-20.2020.	1.9	46

#	ARTICLE	IF	CITATIONS
650	Sexual Dimorphism in the 3xTg-AD Mouse Model and Its Impact on Pre-Clinical Research. Journal of Alzheimer's Disease, 2021, 80, 41-52.	2.6	35
651	Effects of concentrated ambient ultrafine particulate matter on hallmarks of Alzheimer's disease in the 3xTgAD mouse model. NeuroToxicology, 2021, 84, 172-183.	3.0	15
652	Berberine Improves Behavioral and Cognitive Deficits in a Mouse Model of Alzheimer's Disease via Regulation of β -Amyloid Production and Endoplasmic Reticulum Stress. ACS Chemical Neuroscience, 2021, 12, 1894-1904.	3.5	31
653	Retinal Changes in Transgenic Mouse Models of Alzheimer's Disease. Current Alzheimer Research, 2021, 18, 89-102.	1.4	5
655	Neurotrophic Treatment Initiated During Early Postnatal Development Prevents the Alzheimer-Like Behavior and Synaptic Dysfunction. Journal of Alzheimer's Disease, 2021, 82, 631-646.	2.6	10
656	Induced Pluripotent Stem Cell-Derived Neural Precursors Improve Memory, Synaptic and Pathological Abnormalities in a Mouse Model of Alzheimer's Disease. Cells, 2021, 10, 1802.	4.1	17
657	Age and gender differences for the behavioral phenotypes of 3xTg alzheimer's disease mice. Brain Research, 2021, 1762, 147437.	2.2	19
658	Preserved Thermal Pain in 3xTg-AD Mice With Increased Sensory-Discriminative Pain Sensitivity in Females but Affective-Emotional Dimension in Males as Early Sex-Specific AD-Phenotype Biomarkers. Frontiers in Aging Neuroscience, 2021, 13, 683412.	3.4	4
659	IL-17 triggers the onset of cognitive and synaptic deficits in early stages of Alzheimer's disease. Cell Reports, 2021, 36, 109574.	6.4	88
660	Optimization of cerebral organoids: a more qualified model for Alzheimer's disease research. Translational Neurodegeneration, 2021, 10, 27.	8.0	14
661	Intranasal Paclitaxel Alters Alzheimer's Disease Phenotypic Features in 3xTg-AD Mice. Journal of Alzheimer's Disease, 2021, 83, 379-394.	2.6	9
662	Microvascular degeneration occurs before plaque onset and progresses with age in 3xTg AD mice. Neurobiology of Aging, 2021, 105, 115-128.	3.1	11
663	Cortical Synaptic Reorganization Under Chronic Arsenic Exposure. Neurotoxicity Research, 2021, 39, 1970-1980.	2.7	4
664	Dopaminergic dysfunction in the 3xTg-AD mice model of Alzheimer's disease. Scientific Reports, 2021, 11, 19412.	3.3	19
665	Diffusion MRI detects basal forebrain cholinergic abnormalities in the 3xTg-AD mouse model of Alzheimer's disease. Magnetic Resonance Imaging, 2021, 83, 1-13.	1.8	14
666	Hydrogen-rich water ameliorates neuropathological impairments in a mouse model of Alzheimer's disease through reducing neuroinflammation and modulating intestinal microbiota. Neural Regeneration Research, 2022, 17, 409.	3.0	12
667	Animal Models of Metabolic Disorders in the Study of Neurodegenerative Diseases: An Overview. Frontiers in Neuroscience, 2020, 14, 604150.	2.8	31
668	Understanding and Treating Alzheimer's Disease. , 2006, , 49-70.		1

#	ARTICLE	IF	CITATIONS
669	Cognition in Rodents. , 2009, , 159-174.		2
670	Cdk5 as a Drug Target for Alzheimer's Disease. , 2008, , 283-299.		2
671	Role of Calcium in the Pathogenesis of Alzheimer's Disease and Transgenic Models. , 2007, 45, 507-521.		47
672	Animal Models of General Cognitive Ability for Genetic Research into Cognitive Functioning. , 2014, , 257-278.		10
673	A β Infusion and Related Models of Alzheimer Dementia. Neuromethods, 2011, , 347-370.	0.3	7
674	Is Alzheimer's a Disorder of Ageing and Why Don't Mice get it? The Centrality of Insulin Signalling to Alzheimer's Disease Pathology. Research and Perspectives in Alzheimer's Disease, 2010, , 129-152.	0.1	3
675	Imaging in Neurology Research II: PET Imaging of CNS Disorders. , 2011, , 499-513.		5
676	Astroglia in Alzheimer's Disease. Advances in Experimental Medicine and Biology, 2019, 1175, 273-324.	1.6	59
677	Rodent Models of Tauopathies. , 2005, , 529-539.		3
678	Aged Rodents for Biogerontology Research. , 2006, , 393-401.		5
679	Long-Term Dietary Supplementation with Selenium-Enriched Yeast Improves Cognitive Impairment, Reverses Synaptic Deficits, and Mitigates Tau Pathology in a Triple Transgenic Mouse Model of Alzheimer's Disease. Journal of Agricultural and Food Chemistry, 2017, 65, 4970-4979.	5.2	33
680	Timing impairments in early Alzheimer's disease: Evidence from a mouse model.. Behavioral Neuroscience, 2020, 134, 82-100.	1.2	4
682	Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology. Journal of Clinical Investigation, 2004, 114, 121-130.	8.2	381
683	Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology. Journal of Clinical Investigation, 2004, 114, 121-130.	8.2	303
684	Preparation of organotypic brain slice cultures for the study of Alzheimer's disease. F1000Research, 2018, 7, 592.	1.6	31
685	Misfolded Proteins in Neurodegenerative Dementias: Molecular Mechanisms. Dementia and Neurocognitive Disorders, 2012, 11, 38.	1.4	2
686	Formulation of a Medical Food Cocktail for Alzheimer's Disease: Beneficial Effects on Cognition and Neuropathology in a Mouse Model of the Disease. PLoS ONE, 2010, 5, e14015.	2.5	74
687	Allopregnanolone Promotes Regeneration and Reduces β -Amyloid Burden in a Preclinical Model of Alzheimer's Disease. PLoS ONE, 2011, 6, e24293.	2.5	106

#	ARTICLE	IF	CITATIONS
688	Distinct Temporal and Anatomical Distributions of Amyloid- β^2 and Tau Abnormalities following Controlled Cortical Impact in Transgenic Mice. PLoS ONE, 2011, 6, e25475.	2.5	80
689	The Preventive and Therapeutic Effects of Intravenous Human Adipose-Derived Stem Cells in Alzheimer's Disease Mice. PLoS ONE, 2012, 7, e45757.	2.5	135
690	Long-Term In Vivo Imaging of Fibrillar Tau in the Retina of P301S Transgenic Mice. PLoS ONE, 2012, 7, e53547.	2.5	148
691	Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage. Journal of Molecular Neuroscience, 2007, 31, 165-170.	2.3	146
693	Sports-Related Concussions in Youth. , 2014, , .		22
694	Early and progressive deficit of neuronal activity patterns in a model of local amyloid pathology in mouse prefrontal cortex. Aging, 2016, 8, 3430-3449.	3.1	10
695	The Effects of Soluble A β Oligomers on Neurodegeneration in Alzheimer's Disease. Current Pharmaceutical Design, 2014, 20, 2506-2519.	1.9	30
696	Age-Related Mitochondrial Alterations without Neuronal Loss in the Hippocampus of a Transgenic Model of Alzheimer's Disease. Current Alzheimer Research, 2013, 10, 390-405.	1.4	27
697	Targeting TNF-Alpha to Elucidate and Ameliorate Neuroinflammation in Neurodegenerative Diseases. CNS and Neurological Disorders - Drug Targets, 2011, 10, 391-403.	1.4	192
698	Hippocampal Unicellular Recordings and Hippocampal-dependent Innate Behaviors in an Adolescent Mouse Model of Alzheimer's disease. Bio-protocol, 2020, 10, e3529.	0.4	2
699	Methods and models in neurodegenerative and systemic protein aggregation diseases. Frontiers in Bioscience, 2010, 15, 373-96.	2.1	12
701	Role of tau in Alzheimer's dementia and other neurodegenerative diseases. Journal of Applied Biomedicine, 2007, 5, 1-12.	1.7	3
702	Amelioration of Alzheimer's disease pathology and cognitive deficits by immunomodulatory agents in animal models of Alzheimer's disease. Neural Regeneration Research, 2019, 14, 1158.	3.0	27
703	The Potential Role of Epigenetics in Alzheimer's Disease Etiology. Biological Systems, Open Access, 2012, 02, .	0.1	3
704	Adult and neonatal astrocytes exhibit diverse gene expression profiles in response to beta amyloid <i>ex vivo</i>. World Journal of Neuroscience, 2012, 02, 57-67.	0.1	5
705	Increased expression of heme-binding protein 1 early in Alzheimer's disease is linked to neurotoxicity. ELife, 2019, 8, .	6.0	27
706	The Clinical and Neuropathological Features of Sporadic (Late-Onset) and Genetic Forms of Alzheimer's Disease. Journal of Clinical Medicine, 2021, 10, 4582.	2.4	9
707	Trouncing Tau. Science of Aging Knowledge Environment: SAGE KE, 2004, 2004, nf73-nf73.	0.8	0

#	ARTICLE	IF	CITATIONS
708	Creating APP Transgenic Lines in Mice. , 2004, , .		0
710	ANTI-AMYLOID- β IMMUNOTHERAPY AS A TREATMENT FOR ALZHEIMER'S DISEASE. , 2008, , 295-318.		1
712	Neurochemical Aspects of Neurodegenerative Diseases. , 2010, , 249-324.		0
713	Synapses and Alzheimersâ€™s Disease: Effect of Immunotherapy?. , 2011, , 269-287.		0
714	Validation of Animal Models of Dementia: Neurochemical Aspects. Neuromethods, 2011, , 169-185.	0.3	0
715	Metabolism, Roles, and Involvement of Lyso-glycerophospholipids in Neurological Disorders. , 2011, , 73-105.		0
717	From Protein Tangles to Genetic Variants: The Central Role of Tau in Neurodegenerative Disease. , 0, , .		0
719	Animal Models of Alzheimerâ€™s Disease. Springer Protocols, 2014, , 527-540.	0.3	0
720	Proteostasis and Secondary Proteinopathy in Alzheimer?s Disease. , 2014, 04, .		0
721	Evaluation of Caspase-3 mRNA Gene Expression Activity in Amyloid Beta-induced Alzheimerâ€™s Disease Rats. Journal of Medical Sciences (Faisalabad, Pakistan), 2017, 17, 117-125.	0.0	5
722	Preserved functional networks in a hydrocephalic mouse. Matters, 0, , .	1.0	3
725	Recent Advances in Nanotherapeutic Interventions for the Treatment of Alzheimerâ€™s Disease. Current Pharmaceutical Design, 2020, 26, 2257-2279.	1.9	4
726	Animal Models in Neuro Ophthalmology. , 2020, , 401-426.		0
727	Genomics of Alzheimerâ€™s disease. , 2020, , 3-18.		0
728	Somatostatin-evoked A β catabolism in the brain: Mechanistic involvement of $\text{I}\kappa\text{B}$ -endosulfine-KATP channel pathway. Molecular Psychiatry, 2022, 27, 1816-1828.	7.9	11
729	NPY and chronic neurodegenerative disease. , 2006, , 223-244.		3
730	Genetic Models of Alzheimerâ€™s Disease. , 0, , 539-544.		1
733	Hsp70 ATPase Modulators as Therapeutics for Alzheimer's and other Neurodegenerative Diseases. Molecular and Cellular Pharmacology, 2010, 2, 43-46.	1.7	40

#	ARTICLE	IF	CITATIONS
736	Dimebon alters hippocampal amyloid pathology in 3xTg-AD mice. <i>International Journal of Physiology, Pathophysiology and Pharmacology</i> , 2012, 4, 115-27.	0.8	17
742	Cell competition from development to neurodegeneration. <i>DMM Disease Models and Mechanisms</i> , 2021, 14, .	2.4	3
743	Modulation of Neurolipid Signaling and Specific Lipid Species in the Triple Transgenic Mouse Model of Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12256.	4.1	11
745	Age dependence of retinal vascular plexus attenuation in the triple transgenic mouse model of Alzheimer's disease. <i>Experimental Eye Research</i> , 2022, 214, 108879.	2.6	4
746	Surfactant Protein-G in Wildtype and 3xTg-AD Mice: Localization in the Forebrain, Age-Dependent Hippocampal Dot-like Deposits and Brain Content. <i>Biomolecules</i> , 2022, 12, 96.	4.0	3
747	JOTROL, a Novel Formulation of Resveratrol, Shows Beneficial Effects in the 3xTg-AD Mouse Model1. <i>Journal of Alzheimer's Disease</i> , 2022, 86, 173-190.	2.6	7
748	Remembering your A, B, C's: Alzheimer's disease and ABCA1. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 995-1018.	12.0	15
749	The three sisters of fate: Genetics, pathophysiology and outcomes of animal models of neurodegenerative diseases. <i>Neuroscience and Biobehavioral Reviews</i> , 2022, 135, 104541.	6.1	4
750	Administration of mucuna beans (<i>Mucuna pruriens</i> (L.) DC. var. <i>utilis</i>) improves cognition and neuropathology of 3xTg-AD mice. <i>Scientific Reports</i> , 2022, 12, 996.	3.3	4
751	Differences in Immune-Related Genes Underlie Temporal and Regional Pathological Progression in 3xTg-AD Mice. <i>Cells</i> , 2022, 11, 137.	4.1	6
752	The effect of exercise on early sensorimotor performance alterations in the 3xTg-AD model of Alzheimer's disease. <i>Neuroscience Research</i> , 2022, 178, 60-68.	1.9	5
753	Integrated lipidomics and network pharmacology analysis of the protective effects and mechanism of Yuanzhi San on rats with cognitive impairment. <i>Bioorganic and Medicinal Chemistry</i> , 2022, 58, 116651.	3.0	5
754	A Review of the Current Mammalian Models of Alzheimer's Disease and Challenges That Need to Be Overcome. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13168.	4.1	31
755	Porous Optical Chemosensors for Early Detection and Monitoring of Heavy Metals Correlated with Alzheimer's Disease. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
756	Alzheimer's-like tau accumulation in dentate gyrus mossy cells induces spatial cognitive deficits by disrupting multiple memory-related signaling and inhibiting local neural circuit. <i>Aging Cell</i> , 2022, 21, e13600.	6.7	9
757	Impaired Experience-Dependent Refinement of Place Cells in a Rat Model of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2022, , 1-10.	2.6	0
758	Therapeutic strategies for tauopathies and drug repurposing as a potential approach. <i>Biochemical Pharmacology</i> , 2022, 198, 114979.	4.4	7
759	Advancements in the development of multi-target directed ligands for the treatment of Alzheimer's disease. <i>Bioorganic and Medicinal Chemistry</i> , 2022, 61, 116742.	3.0	37

#	ARTICLE	IF	CITATIONS
762	A New Insight into an Alternative Therapeutic Approach to Restore Redox Homeostasis and Functional Mitochondria in Neurodegenerative Diseases. <i>Antioxidants</i> , 2022, 11, 7.	5.1	5
763	Riluzole restores memory and brain energy metabolism in A β PP-PS1 mouse model of Alzheimer's disease. <i>Biochemical and Biophysical Research Communications</i> , 2022, 610, 140-146.	2.1	2
768	Cell competition from development to neurodegeneration. <i>DMM Disease Models and Mechanisms</i> , 2021, 14, .	2.4	8
769	Adolescent Binge Alcohol Enhances Early Alzheimer's Disease Pathology in Adulthood Through Proinflammatory Neuroimmune Activation. <i>Frontiers in Pharmacology</i> , 2022, 13, 884170.	3.5	24
770	Age Related Changes in Muscle Mass and Force Generation in the Triple Transgenic (3xTgAD) Mouse Model of Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 876816.	3.4	6
771	Transgenic Mouse Models of Alzheimer's Disease: An Integrative Analysis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5404.	4.1	36
772	Heightened Tameless and Accelerated Handling-Habituation in 3 \times Tg-AD Mice on a B6;129 Genetic Background. <i>Journal of Alzheimer's Disease Reports</i> , 2022, 6, 245-255.	2.2	4
773	Olfactory Evaluation in Alzheimer's Disease Model Mice. <i>Brain Sciences</i> , 2022, 12, 607.	2.3	7
774	Mechanisms of Mitochondrial Malfunction in Alzheimer's Disease: New Therapeutic Hope. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-28.	4.0	16
775	Effects of Ultramicrosized Palmitoylethanolamide on Mitochondrial Bioenergetics, Cerebral Metabolism, and Glutamatergic Transmission: An Integrated Approach in a Triple Transgenic Mouse Model of Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, .	3.4	4
776	Alterations in Retinal Signaling Across Age and Sex in 3xTg Alzheimer's Disease Mice. <i>Journal of Alzheimer's Disease</i> , 2022, 88, 471-492.	2.6	3
778	The Effects of Physical Running on Dendritic Spines and Amyloid-beta Pathology in 3xTg-AD Male Mice. , 2022, 13, 1293.		10
779	HEBP1 - An early trigger for neuronal cell death and circuit dysfunction in Alzheimer's disease. <i>Seminars in Cell and Developmental Biology</i> , 2023, 139, 102-110.	5.0	6
780	Diabetes and cognitive dysfunction. , 2023, , 185-201.		2
781	Non-Invasive Nasal Discharge Fluid and Other Body Fluid Biomarkers in Alzheimer's Disease. <i>Pharmaceutics</i> , 2022, 14, 1532.	4.5	3
782	X-ray multiscale 3D neuroimaging to quantify cellular aging and neurodegeneration postmortem in a model of Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 4338-4357.	6.4	5
783	FAK-Mediated Signaling Controls Amyloid Beta Overload, Learning and Memory Deficits in a Mouse Model of Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2022, 23, 9055.	4.1	4
784	Impact of alcohol-induced intestinal microbiota dysbiosis in a rodent model of Alzheimer's disease. <i>Frontiers in Aging</i> , 0, 3, .	2.6	2

#	ARTICLE	IF	CITATIONS
785	Development of a system to analyze oral frailty associated with Alzheimer's disease using a mouse model. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	3.4	5
786	Inhibition of PLK2 activity affects APP and tau pathology and improves synaptic content in a sex-dependent manner in a 3xTg mouse model of Alzheimer's disease. <i>Neurobiology of Disease</i> , 2022, 172, 105833.	4.4	3
787	Brain microstructure abnormalities in the 3xTg-AD mouse – A diffusion MRI and morphology correlation study. <i>Magnetic Resonance Imaging</i> , 2022, 94, 48-55.	1.8	1
788	Tetrandrine ameliorates cognitive deficits and mitigates tau aggregation in cell and animal models of tauopathies. <i>Journal of Biomedical Science</i> , 2022, 29, .	7.0	18
789	Age-Related Oxidative Redox and Metabolic Changes Precede Intraneuronal Amyloid- β^2 Accumulation and Plaque Deposition in a Transgenic Alzheimer's Disease Mouse Model. <i>Journal of Alzheimer's Disease</i> , 2022, 90, 1501-1521.	2.6	4
790	Ovariectomy-induced hormone deprivation aggravates A β^{1-42} deposition in the basolateral amygdala and cholinergic fiber loss in the cortex but not cognitive behavioral symptoms in a triple transgenic mouse model of Alzheimer's disease. <i>Frontiers in Endocrinology</i> , 0, 13, .	3.5	3
791	An emerging role of astrocytes in aging/neuroinflammation and gut-brain axis with consequences on sleep and sleep disorders. <i>Ageing Research Reviews</i> , 2023, 83, 101775.	10.9	14
792	Dual modulators of aggregation and dissociation of amyloid beta and tau: In vitro, in vivo, and in silico studies of <i>Uncaria rhynchophylla</i> and its bioactive components. <i>Biomedicine and Pharmacotherapy</i> , 2022, 156, 113865.	5.6	6
793	Sex-dependent worsening of NMDA-induced responses, anxiety, hypercortisolemia, and organometry of early peripheral immunoendocrine impairment in adult 3xTg-AD mice and their long-lasting ontogenic modulation by neonatal handling. <i>Behavioural Brain Research</i> , 2023, 438, 114189.	2.2	2
794	Sex- and Neuropsychiatric-Dependent Circadian Alterations in Daily Voluntary Physical Activity Engagement and Patterns in Aged 3xTg-AD Mice. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13671.	4.1	0
796	New Insights into Microglial Mechanisms of Memory Impairment in Alzheimer's Disease. <i>Biomolecules</i> , 2022, 12, 1722.	4.0	9
797	Early diagnosis and treatment of Alzheimer's disease by targeting toxic soluble A β^2 oligomers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	7.1	18
798	Preclinical Models for Alzheimer's Disease: Past, Present, and Future Approaches. <i>ACS Omega</i> , 2022, 7, 47504-47517.	3.5	14
799	The Contribution of Transgenic Models to the Understanding of Alzheimer's Disease Progression and Therapeutic Development. , 2011, , 1-14.		0
800	Animal Models of Amyloid/PS-1 Pathology. , 2011, , 15-38.		0
801	A simple genetic stratification method for lower cost, more expedient clinical trials in early Alzheimer's disease: A preliminary study of tau PET and cognitive outcomes. <i>Alzheimer's and Dementia</i> , 0, , .	0.8	0
802	Genetic removal of synaptic Zn ²⁺ impairs cognition, alters neurotrophic signaling and induces neuronal hyperactivity. <i>Frontiers in Neurology</i> , 0, 13, .	2.4	0
803	Compensatory remodeling of a septo-hippocampal GABAergic network in the triple transgenic Alzheimer's mouse model. <i>Journal of Translational Medicine</i> , 2023, 21, .	4.4	3

#	ARTICLE	IF	CITATIONS
804	Assessment of complementary white matter microstructural changes and grey matter atrophy in a preclinical model of Alzheimer's disease. <i>Magnetic Resonance Imaging</i> , 2023, 101, 57-66.	1.8	0
805	Exposure to Low Levels of Radiofrequency Electromagnetic Fields Emitted from Cell-phones as a Promising Treatment of Alzheimer's Disease: A Scoping Review Study. <i>Journal of Biomedical Physics and Engineering</i> , 2023, 13, .	0.9	0
806	Phospholipase D1 Attenuation Therapeutics Promotes Resilience against Synaptotoxicity in 12-Month-Old 3xTg-AD Mouse Model of Progressive Neurodegeneration. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3372.	4.1	1
807	Aza-Residue Modulation of Cyclic <sc>d</sc>,<sc>l</sc>-Î±-Peptide Nanotube Assembly with Enhanced Anti-Amyloidogenic Activity. <i>Journal of Medicinal Chemistry</i> , 2023, 66, 3058-3072.	6.4	3
808	Increased Expression of Autophagy-Related Genes in Alzheimer's Disease"Type 2 Diabetes Mellitus Comorbidity Models in Cells. <i>International Journal of Environmental Research and Public Health</i> , 2023, 20, 4540.	2.6	2
809	Neuroanatomical and morphometric study of S100Î² positive astrocytes in the entorhinal cortex during ageing in the 3xTg-Alzheimer's disease mouse model. <i>Neuroscience Letters</i> , 2023, 802, 137167.	2.1	2
810	A novel system to analyze oral frailty of mice. <i>Aging</i> , 2023, 15, 2362-2363.	3.1	0
811	Geroprotective interventions in the 3xTg mouse model of Alzheimer's disease. <i>GeroScience</i> , 0, , .	4.6	2
812	Progressive sleep disturbance in various transgenic mouse models of Alzheimer's disease. <i>Frontiers in Aging Neuroscience</i> , 0, 15, .	3.4	0
813	Personalized Explanations for Early Diagnosis of Alzheimer's Disease Using Explainable Graph Neural Networks with Population Graphs. <i>Bioengineering</i> , 2023, 10, 701.	3.5	2
814	Cannabinoids and endocannabinoid signaling at the basal forebrain cholinergic system. , 2023, , 417-430.		0
815	Transcriptomic Analyses of Neurotoxic Astrocytes Derived from Adult Triple Transgenic Alzheimer's Disease Mice. <i>Journal of Molecular Neuroscience</i> , 2023, 73, 487-515.	2.3	1
816	Glutamine Supplementation Preserves Glutamatergic Neuronal Activity in the Infralimbic Cortex, Which Delays the Onset of Mild Cognitive Impairment in 3Å—Tg-AD Female Mice. <i>Nutrients</i> , 2023, 15, 2794.	4.1	2
817	Quantitative microglia morphological features correlate with diffusion MRI in 2-month-old 3xTg-AD mice. <i>Magnetic Resonance Imaging</i> , 2023, , .	1.8	0
818	Sleep deprivation modulates APOE and LDL receptor-related protein 1 through thyroid hormone T4 and impairs AÎ² clearance in hippocampus of rats. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2023, 1869, 166729.	3.8	0
819	Investigating the Synergistic Potential of Low-Dose HDAC3 Inhibition and Radiotherapy in Alzheimer's Disease Models. <i>Molecular Neurobiology</i> , 2023, 60, 4811-4827.	4.0	0
820	Reversal of Tau-Dependent Cognitive Decay by Blocking Adenosine A1 Receptors: Comparison of Transgenic Mouse Models with Different Levels of Tauopathy. <i>International Journal of Molecular Sciences</i> , 2023, 24, 9260.	4.1	2
821	Metabolic reprogramming in inflammatory microglia indicates a potential way of targeting inflammation in Alzheimer's disease. <i>Redox Biology</i> , 2023, 66, 102846.	9.0	3

#	ARTICLE	IF	CITATIONS
822	Low-Dose Chidamide Treatment Displays Sex-Specific Differences in the 3xTg-AD Mouse. <i>Biomolecules</i> , 2023, 13, 1324.	4.0	0
823	Evidence of disturbed insulin signaling in animal models of Alzheimer's disease. <i>Neuroscience and Biobehavioral Reviews</i> , 2023, 152, 105326.	6.1	2
824	Survival Bias, Non-Linear Behavioral and Cortico-Limbic Neuropathological Signatures in 3xTg-AD Mice for Alzheimer's Disease from Premorbid to Advanced Stages and Compared to Normal Aging. <i>International Journal of Molecular Sciences</i> , 2023, 24, 13796.	4.1	3
825	The behavioral, pathological and therapeutic features of the triple transgenic Alzheimer's disease (3xTg-AD) mouse model strain. <i>Experimental Neurology</i> , 2023, 368, 114505.	4.1	0
826	Non-conducting functions of potassium channels in cancer and neurological disease. <i>Current Topics in Membranes</i> , 2023, , .	0.9	0
827	Mammalian Models in Alzheimer's Research: An Update. <i>Cells</i> , 2023, 12, 2459.	4.1	1
828	Proposed mechanisms of tau: relationships to traumatic brain injury, Alzheimer's disease, and epilepsy. <i>Frontiers in Neurology</i> , 0, 14, .	2.4	0
829	Cognitive trajectories in longitudinally trained 3xTg-AD mice. <i>Physiology and Behavior</i> , 2024, 275, 114435.	2.1	0
830	Signature of paraoxonases in the altered redox homeostasis in Alzheimer's disease. <i>Chemico-Biological Interactions</i> , 2024, 388, 110839.	4.0	0
832	Astrocyte S100 β expression and selective differentiation to GFAP and GS in the entorhinal cortex during ageing in the 3xTg-Alzheimer's disease mouse model. <i>Acta Histochemica</i> , 2024, 126, 152131.	1.8	0
833	Akt activation ameliorates deficits in hippocampal-dependent memory and activity-dependent synaptic protein synthesis in an Alzheimer's disease mouse model. <i>Journal of Biological Chemistry</i> , 2024, 300, 105619.	3.4	0
835	Investigating metabolic dysregulation in serum of triple transgenic Alzheimer's disease male mice: implications for pathogenesis and potential biomarkers. <i>Amino Acids</i> , 2024, 56, .	2.7	0
836	A Chronic Increase in Blood-Brain Barrier Permeability Facilitates Intraneuronal Deposition of Exogenous Bloodborne Amyloid-Beta1-42 Peptide in the Brain and Leads to Alzheimer's Disease-Relevant Cognitive Changes in a Mouse Model. <i>Journal of Alzheimer's Disease</i> , 2024, 98, 163-186.	2.6	0
837	OCT Imaging in Murine Models of Alzheimer's Disease in a Systematic Review: Findings, Methodology and Future Perspectives. <i>Biomedicines</i> , 2024, 12, 528.	3.2	0
838	Insights on the Use of Transgenic Mice Models in Alzheimer's Disease Research. <i>International Journal of Molecular Sciences</i> , 2024, 25, 2805.	4.1	0
839	Modulation of hippocampal protein expression by a brain penetrant biologic TNF- α inhibitor in the 3xTg Alzheimer's disease mice. <i>Journal of Translational Medicine</i> , 2024, 22, .	4.4	0